

Effectiveness of revascularisation of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review

R. J. Hinchliffe¹, J. R. W. Brownrigg¹, G. Andros², J. Apelqvist³, E. J. Boyko⁴, R. Fitridge⁵, J. L. Mills⁶, J. Reekers⁷, C. P. Shearman⁸, R. E. Zierler⁹, N. C. Schaper¹⁰; on behalf of the International Working Group on the Diabetic Foot (IWGDF)

¹St George's Vascular Institute, St George's Healthcare NHS Trust, London, UK

²Amputation Prevention Center, Valley Presbyterian Hospital, Los Angeles, CA, USA

³Department of Endocrinology, University Hospital of Malmö, Sweden

⁴Seattle Epidemiologic Research and Information Centre-Department of Veterans Affairs Puget Sound Health Care System and the University of Washington, Seattle, WA, USA

⁵Vascular Surgery, The University of Adelaide, Adelaide, South Australia, Australia

⁶SALSA (Southern Arizona Limb Salvage Alliance), University of Arizona Health Sciences Center, Tucson, Arizona, USA

⁷Department of Vascular Radiology, Amsterdam Medical Centre, The Netherlands

⁸Department of Vascular Surgery, Southampton University Hospitals NHS Trust, UK

⁹Department of Surgery, University of Washington, Seattle, Washington, USA

¹⁰Div. Endocrinology, MUMC+, CARIM Institute, Maastricht, The Netherlands

Address of correspondence:

Mr R.J. Hinchliffe MD, FRCS
Reader / Consultant in Vascular Surgery
St George's Vascular Institute
4th Floor, St James Wing
St George's University Hospitals NHS Foundation Trust
Blackshaw Road
London
SW17 0QT
email: rhinchli@sgul.ac.uk

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/dmrr.2705

Summary

Symptoms or signs of peripheral artery disease (PAD) can be observed in up to 50% of the patients with a diabetic foot ulcer and is a risk factor for poor healing and amputation. In 2012 a multidisciplinary working group of the International Working Group on the Diabetic Foot published a systematic review on the effectiveness of revascularization of the ulcerated foot in patients with diabetes and PAD. This publication is an update of this review and now includes the results of a systematic search for therapies to revascularize the ulcerated foot in patients with diabetes and PAD from 1980 – June 2014. Only clinically relevant outcomes were assessed. The research conformed to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, and the Scottish Intercollegiate Guidelines Network methodological scores were assigned. A total of 56 papers were eligible for full text review. There were no randomized controlled trials, but there were four nonrandomized studies with a control group. The major outcomes following endovascular or open bypass surgery were broadly similar among the studies. Following open surgery, the 1-year limb salvage rates were a median of 85% (interquartile range of 80–90%), and following endovascular revascularization, these rates were 78% (70–89%). At 1-year follow-up, 60% or more of ulcers had healed following revascularization with either open bypass surgery or endovascular techniques. Studies appeared to demonstrate improved rates of limb salvage associated with revascularization compared with the results of conservatively treated patients in the literature. There were insufficient data to recommend one method of revascularization over another. There is a real need for standardized reporting of baseline demographic data, severity of disease and outcome reporting in this group of patients.

Keywords: diabetic foot; ulcer; peripheral artery disease; amputation; diabetes

Abbreviations: ABI: ankle-brachial pressure index; AHA: American Heart Association; AKA: above knee amputation; ARF: acute renal failure; AT: anterior tibial artery; BKA: below knee amputation; CAD: coronary artery disease; CBA: control before and after (study design); CFA: common femoral artery; CIA: common iliac artery; CKD: chronic kidney disease; CLI: critical limb ischaemia; CVD: cerebrovascular disease; DFU: diabetic foot ulcer; DM: diabetes mellitus; DP: dorsalis pedis artery; IQR: interquartile range; ITS: interrupted time series (study design); ITT: intention to treat (analysis); IWGDF: International Working Group on the Diabetic Foot; MI: myocardial infarction; MRA: Magnetic Resonance Angiography; NA: not available; NPWT: negative pressure wound

therapy; NR: not reported; NYHA: New York Heart Association; PAD: peripheral artery disease; PT: posterior tibial artery; PTA: percutaneous transluminal angioplasty; RCT: randomised controlled trial; SD: standard deviation; SFA: superficial femoral artery; SIGN: Scottish Intercollegiate Guidelines Network; TASC: The Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Artery Disease; TBI: toe-brachial pressure index; TcpO₂: transcutaneous oxygen tension; UT: University of Texas (wound classification system).

Introduction

In 2012 a multidisciplinary group of experts of the International Working Group on the management of the Diabetic Foot (IWDFG) published a systematic review on the effectiveness of revascularisation in patients with a diabetic foot ulcer and peripheral artery disease (PAD)¹. Since this publication several new studies on this topic have been published and this current review is an update of the 2012 publication; using the same search strategy we added new information to the original publication with shortening of some sections of the first publication. This systematic review is also the basis for our Guidance document on the diagnosis, prognosis and interventions for patients with PAD and diabetic foot ulceration, which is published separately in this journal².

PAD and infection are the major causes of lower leg amputation in persons with diabetes^{3,4}. Diabetes is a risk factor for PAD and depending on the definitions used, prevalence rates of 10% to 40% in the general population of patients with diabetes have been reported^{5,6,7,8}. In large observational studies PAD, ranging from relatively mild disease with limited effects on wound healing to severe limb ischemia with delayed wound healing, was present in up to 50% of the patients with a diabetic foot ulcer^{9,10,11}. The relatively poor outcome of ischemic foot ulcers in diabetes is probably related to a combination of factors, including the anatomic distribution of the vascular lesions rendering them more difficult to treat, the association with other abnormalities like infection, neuropathy and renal failure and the presence of abnormalities in other vascular territories, such as the coronary or cerebral arteries^{7, 9,12,13,14}. The mortality of these patients is high with 50% of patients dead at 5 years¹⁵. The effect of PAD on wound healing will relate in part to its severity and extent but also on other factors such as poor glycemic control, microvascular dysfunction, impaired formation of collateral vessels, increased mechanical loading of the ulcer region and comorbidities mentioned above¹⁶.

PAD in patients with diabetes has a number of characteristics that renders it more difficult to treat. The atherosclerotic lesions are multilevel and particularly severe in tibial arteries, with a high prevalence of long occlusions¹⁷. The predilection for multiple crural vessel involvement combined with extensive arterial calcification increases the technical challenges associated with revascularisation using either open bypass or endovascular techniques. In the last decades new techniques and technologies have been introduced for treating PAD, which might be relevant to the patient with diabetes and a poorly healing ischemic foot ulcer. In particular encouraging results have been reported on endovascular approaches and the field is rapidly evolving^{18,19}.

Materials and Methods

We searched the Medline and Embase databases for articles related to therapies to revascularize the ulcerated foot in patients with diabetes and PAD published from January 1980 – June 2014 (Appendix 1). Due to the changing nature of interventions for PAD and improving technology we excluded studies before 1980. PAD was defined for the purpose of this systematic review as any flow limiting atherosclerotic lesion of the arteries below the inguinal ligament. All patients included had to have objective evidence of PAD (e.g. angiography or MRA). We only included studies in the English language.

We only selected studies in which >80% of patients had evidence of tissue loss (defined as any lesion of the skin breaching the epithelium or ulceration or gangrene). The diagnosis of diabetes was made according to the individual publication. We included studies of more than 40 patients where >80% of the population had diabetes or when the results of at least 30 patients with diabetes were reported separately. Studies solely reporting interventions on aortic and iliac arterial disease were excluded because the treatment of supra-inguinal disease in people with diabetes does not differ markedly from that in non-diabetic individuals. We also excluded: studies that had only data on quality of life, on costs, on diagnosis and prognosis of PAD; that were only concerned with medical or topical therapy or on improvement of oxygen delivery; and, that compared one form of revascularisation technology with another (for example various atherectomy devices). Only studies reporting ulcer healing, limb salvage, major amputation or survival as the primary outcome measures were included in the review. Early morbidity or mortality was considered within 30 days or within the first hospital admission. A major complication was defined as any which resulted

in a systemic disturbance of the patient or prolonged hospitalisation (or as defined by the reporting study).

Patient demographics that were assessed included age, sex, ethnicity and comorbidities (cardiovascular, renal and cerebrovascular). We extracted the specifics of the foot lesions where possible, such as site on the foot, depth, presence of infection and stratified when possible according to any previously reported and validated diabetic foot ulcer scoring system. The anatomical distribution of PAD was extracted according to the site of the disease; standard reporting systems were included where possible (e.g. TASC²⁰ or Bollinger systems²¹). Objective assessment of perfusion was reported when possible, which included ankle-brachial pressure index (ABI), toe pressure and transcutaneous oxygen concentration (T_{cp}O₂). We made no distinction among various endovascular techniques (e.g. angioplasty, stenting, subintimal angioplasty, atherectomy), all being referred to as “endovascular therapy” or various bypass techniques (e.g. in situ versus reversed venous bypass).

The systematic search was performed according to PRISMA guidelines²². Two reviewers assessed studies for inclusion based on titles; two reviewers then excluded studies based on review of the abstract; and reviewed the full text of selected articles for quality rating; the data for the evidence table was extracted by one author. Studies were assessed for methodological robustness, using the Scottish Intercollegiate Guidelines Network (SIGN) instrument as follows: Level 1 includes meta-analyses and Randomized Controlled Trials (RCTs), Level 2 includes studies with case-control, cohort, controlled-before-after (CBA) or interrupted time series (ITS) design. Studies were rated as: ++ (high quality with low risk of bias), + (well conducted with low risk of bias) and – (low quality with higher risk of bias), according to the SIGN methodological quality score²³. Level 3 studies, i.e. those without a control group, such as case series, were not rated. Pooling of data (and therefore weighting of studies) was not possible due to study heterogeneity and the generally low quality of evidence (see below). When several studies reported on a specific item we have summarised the data of these separate studies as inter-quartile ranges and median. It should be noted that these figures are not weighted means.

Results

After the identification and screening phase 958 articles were assessed for eligibility 57 papers were finally selected for full text review. These articles described revascularisation of

the ulcerated foot in 9029 patients with diabetes and PAD (Table 1). There were no randomised controlled trials but there were four non-randomised studies with an intervention and control group^{31,47,57,72}. These were all of low quality and potentially subject to significant bias (SIGN 2-). Moreover, there were five recent studies comparing the effect of the direct and indirect revascularisation, according to the angiosome concept⁷⁵⁻⁷⁹. Also these studies had a high risk of bias and were graded as SIGN 2-. The remaining 56 papers were case series (SIGN 3). Studies reported bypass surgery, endovascular therapy or both techniques used in combination. Although most reports adequately presented patient demographics and comorbidities, a major limitation was that few studies adequately reported or categorized either baseline foot lesions or PAD severity. A number of studies were reported from the same institution and it is likely that some patients were reported more than once.

Patient demographics and comorbidities

The median reported proportion of males in the included studies was 66% (inter-quartile ranges 60-74%), and the median reported age was 69 years (inter-quartile ranges 65-71 years). Patients with diabetes, PAD and foot ulcers had a prevalence of comorbidities. Specifically, the prevalence of coronary artery disease was reported as 38% – 59% (inter-quartile ranges) with a median of 47%, of cerebrovascular disease as 18% – 23% with a median of 21% and of end-stage renal disease as 11% – 41% with a median of 20% (although the definition varied from study to study and in some studies was only reported as renal impairment). Eight studies did not report any data on comorbidity and data on severity of comorbidities (e.g. NYHA classifications) were sparse.

Wound healing

Wound healing was only reported in seven studies^{25, 30, 33, 35, 59, 65, 66}. Only one study defined wound healing at a pre-defined time point of 12 months⁵⁹. Overall, for the seven studies of endovascular and two of bypass surgery the ulcer healing rate was 60% or more at 12 months follow-up.

Angioplasty-first strategy

Three studies, with a mean follow-up of 20, 25 and 26 months reported on an angioplasty-first strategy, where angioplasty was the preferred first-line option for revascularisation (scoring of anatomical distribution was not given)^{65, 30, 39}. In one of these studies, a large series of 993 consecutive patients with diabetes hospitalised with foot ulcer or ischemic rest

pain and PAD, percutaneous angioplasty (PTA) was technically not feasible in 16% of the patients due to complete calcified occlusion of the vessel precluding balloon catheter passage³⁰. PTA did not establish in line flow to the foot in only 1% of patients. The second study was a consecutive series of 100 patients considered suitable for an infra-inguinal PTA first approach and 11% of the patients required bypass surgery for a failed PTA³⁹. In the third study from a tertiary referral hospital, angioplasty was attempted in 456 (89.4%) of 510 patients; it was a technical failure in 11%. Mortality and limb salvage rates were comparable to the other series⁶⁵.

Crural vessel angioplasty

Crural PTA employed as a revascularisation technique in isolation was reported in five studies^{27, 32, 35, 67, 69,72,73}. Studies variously reported limb salvage outcomes, all of which exceeded 63% at 18 months (and up to 93% at 35 months).

Pedal bypass grafts

Ten studies reported the results of pedal bypass grafting (one of which focused on outcomes in patients with ESRD). Studies reported limb salvage rates in a median of 86% with an inter-quartile range of 85–98% at one year, a median of 88.5 (81.3–82.3%) at three years and 78% (78– 82.3%) at five years. However, the numbers available for follow-up at three and five years were low; the distribution / severity of PAD and the type of foot lesion were poorly reported.

Angiosome directed therapy

Five retrospective studies with a high risk of bias analysed the outcome of revascularisation according to the angiosome concept, in which the foot can be divided into three-dimensional blocks of tissue, each with its own feeding artery. According to this concept, direct revascularisation results in a restoration of pulsatile blood flow through a feeding artery to the area where the ulcer is located, while with indirect revascularisation flow is restored through collateral vessels deriving from neighbouring angiosomes⁸⁰. In these studies post-procedural angiograms were scored as either direct flow to site of the ulcer by a feeding artery (direct revascularisation) or indirect flow through collaterals (indirect revascularisation). Three studies reported significantly higher limb salvage rate after direct revascularisation⁷⁵⁻⁷⁷, while in two no differences were observed^{78,79}. Ulcer healing was also reported to be significantly higher after direct revascularisation in three studies^{75,78,79}. Söderström et al therefore analysed

their data using propensity scores in order to reduce confounding and reported a significantly increased healing rate after direct vs. indirect revascularisation: 69% vs. 47% after 1 year, respectively, but without any difference in limb salvage⁷⁸. Acin et al further divided the patients with indirect revascularisation in two groups: those with indirect flow through collaterals and those with indirect flow but no visible collaterals⁷⁶. The latter group had the poorest results, with ulcer healing rate of only 7% after 1 year and limb salvage rate of 59% after 2 years. The direct and indirect through collaterals revascularisations had comparable outcomes with healing rates of 66% vs. 68% and limb salvage rates of 89% vs. 85%, respectively. These authors suggest that restoration of blood flow to an ischemic ulcer is pivotal, with similar results of flow through medium or large size collaterals or via the feeding artery.

Infection

Only two studies specifically reported the outcomes of a revascularisation procedure in patients presenting with foot infection, PAD and diabetes^{62, 61}. In these studies the mortality rates at one year were 5% and 19%, respectively. Limb outcomes were poorly described but limb salvage was 98% in one study at one year⁶¹.

End-stage renal disease

Patients with end-stage renal disease (ESRD) were identified in nine studies^{40, 43, 47, 52, 58, 67}. The definition of ESRD varied and included patients who were and who were not receiving renal dialysis and those with functioning renal transplants. The 30-day mortality in these patients was 4.6% (inter-quartile range 2.6% – 8.8%) but one year mortality was high at 38% (inter-quartile range 25.5–41.5%). In survivors, one year limb salvage rates were a median of 70% (inter-quartile range 65–75%). Long-term outcomes were also poor with reported mortalities (when available) at 2 years of 48%⁴³ and 72%⁴⁰, at 3 years 56%⁵⁸ and at 5 years 91%⁴⁷.

Early complications

Methods for reporting early complications were varied. Major systemic complications were frequent in both patients undergoing bypass surgery and endovascular procedures; the majority of studies reported major systemic complications in the region of 10%, with similar rates for endovascular and bypass surgery.

Peri-operative mortality

30-day or in-hospital mortality was described in 33 studies. The peri-operative mortality in the two types of procedures were similar: following open surgery it was reported in 23 studies with an inter-quartile range of 1-5%, with a median of 2%; in endovascular procedures the interquartile range was 0–5.5% with a median of 1%. In both open and endovascular series there were several outlying studies with either no mortality or a mortality rate of 9% or greater. It was not clear why these results were so different. As the severity of comorbidities frequently was not stated it was difficult to infer the effect of comorbidity on outcomes.

Mortality

Mortality at one year or longer following intervention was reported more frequently in studies describing open surgery. Mortality at one year follow-up reported in these studies (n=15) had an inter-quartile range of 13% – 36%, with a median of 20% and at five years: 40.8% – 80.5% with a median of 50.5%. There was a paucity of long-term follow-up data in patients having undergone endovascular procedures. Seven studies reported on one-year follow-up of patients undergoing endovascular procedures with mortality rates of median 7% (inter-quartile ranges 5.0%-10.0); five year follow-up mortality rate was reported in only two studies and varied widely (5% and 74%).

Limb salvage and Amputation

After five years the median limb salvage rate was of 77.5% (inter-quartile range 72% – 82.5%). Following an endovascular procedure the limb salvage rates within 1 year had an interquartile range of 70%–89%, with a median of 78%, (7 studies); 3 years data were reported in 4 studies with an inter-quartile range of 63% – 80.0% and a median of 77%. After five years the limb salvage was 56% and 77% in the two studies in which it was reported.

Major amputation rates were reported by 37 studies. The definition of major amputation was not always specified and sometimes differed among studies. The median number of major amputations within 30 days was 3.5% (range 2%-5%) based on five studies. The limb salvage rates within 12 months following open surgery were reported in 21 studies and had an inter-quartile range of 80–90%, with a median of 85%; after 3 years these figures were 71%-90% and 80% (9 studies). The study by Malmstedt was an interpretation of the Swedish national vascular registry, Swedvasc, and therefore represents the results of a number of different

vascular centres rather than those simply focussed on distal bypass procedures⁴⁴. The registry provided a composite outcome for ipsilateral amputation or death per 100 person years of 30.2 (95% CI 26.6 – 34.2) at a median follow-up of 2.2 years. The median time to reach this end-point in patients with diabetes and PAD undergoing bypass surgery (82% for ulceration) was 2.3 years.

Minor amputation rates varied widely (from 12% to 92%) in the 12 studies reporting on this complication with a median of 38% (inter-quartile range 23–59%). It was not clear whether patients received one or more minor amputations in any particular study. The rates of minor amputations for open surgery studies had a median of 36% (inter-quartile range 23–57%) and those for endovascular studies had a median of 38% (inter-quartile range 23–57%). However, the number of studies reporting this complication was small and the demographics were heterogeneous.

Discussion

This systematic review is an update of our 2012 report. It examines the evidence to support the effectiveness of revascularisation of the ulcerated foot in patients with diabetes and PAD. Up to 50% of the patients with diabetes and a foot ulcer have signs of PAD, which can have a major impact on ulcer healing and the risk for lower leg amputation^{3, 81, 82}. Early reports on the effectiveness of revascularisation in patients with diabetes and PAD were not encouraging and led some to suggest that diabetes was associated with a characteristic occlusive small vessel arteriopathy, consequently leading to a nihilistic attitude toward revascularisation. However, subsequent studies indicated that revascularisation can have good results in patients with diabetes and an ischemic foot ulcer⁸³, but these patients represent a unique problem among patients with PAD.

In our 1980-2010 review 49 studies were identified fulfilling our selection criteria and our current review resulted in 8 additional studies. The quality of studies included in this review was frequently low. As there are no studies in which patients with an ischemic foot ulcer were randomised into either revascularisation or conservative treatment, it remains difficult to determine the effectiveness of revascularisation in these patients. It is also unlikely that such a study will ever be performed. Also the natural history of patients with PAD and an ulcerated foot remains poorly defined. But, in two studies that reported the outcomes of

patients with diabetes and CLI who were **not** revascularized, the limb salvage rate was 54% at one year^{84, 85} much lower than the 78% and 85% in the series presented here.

Ulceration of the foot in diabetes is often a complex interplay of many etiologic factors, and the situation is compounded by the presence and severity of PAD². Although the current data indicate that revascularisation should always be considered in a patient with diabetes, foot ulceration and severe ischemia, it still remains unclear if such procedures have an added value in cases of mild-moderate perfusion deficits. There was little data to inform on the indications or timing for either diagnostic angiography or intervention among the studies.

There are currently no RCTs directly comparing open vs. endovascular revascularisation techniques in diabetic patients with an ischemic foot ulcer. However, broadly speaking the major outcomes appeared similar across all studies where revascularisation of the foot was successful. This conclusion is in line with two meta-analyses on the outcomes of pedal bypass grafting and crural angioplasty, although different inclusion criteria were used; the majority of patients in these two meta-analyses had diabetes^{86,87}. In two studies of consecutive patients with diabetes included in our review where angioplasty was the preferred first-line option for revascularization, bypass surgery was only required in a minority^{31, 40}. However, the results of both open and endovascular procedures will greatly depend upon the expertise in a given centre.

Traditionally, revascularization of the lower limb is aimed at the best vessel supplying in-line flow to the foot¹⁸. Recent case series have tried to establish whether a new approach in which the angiosome is revascularized that directly supplies the area of ulceration will improve outcome. According to this theory, the foot can be divided into three-dimensional blocks of tissue, angiosomes, each with its own feeding artery. Restoration of pulsatile blood flow through this feeding artery is thought to have better results than when flow is restored through collaterals deriving from neighbouring angiosomes. We identified five studies with conflicting results and high risk of bias precluding drawing firm conclusions⁷⁵⁻⁷⁹. Moreover, due to the high variability in populations and the lack of a clear definition angiosome we do not believe that the results cannot be pooled. In contrast, a recent meta-analysis concluded that the angiosome approach may improve in ischemic foot ulcers wound healing and limb salvage rates, compared with indirect revascularization⁸⁸. This disparity will only be resolved

by well-structured, prospective studies, in combination with new imaging techniques that enable objective evaluation of regional blood flow during a revascularisation procedure^{89,90}.

The variability in outcomes after revascularisation is probably related to the large variability of patients included in these observational studies, with some patients having only relative mild PAD and others having severe ischemia, infection and multiple comorbidities. In particular, end-stage renal disease is a strong risk factor for both foot ulceration and amputation in patients with diabetes⁹¹. These patients are frequently difficult to treat and long-term mortality is high, which might negatively influence the decision to perform a revascularisation procedure. However, our data indicate that even in these patients favourable results can be obtained. The majority of studies reported 1-year limb salvage rates of 65-75% after revascularisation in survivors.

Although peri-operative mortality rates were generally low, given associated comorbidities, peri-operative major systemic complications were around 10%. It is possible that part of these major complications were more related to the poor general health status of the patients rather than to the revascularisation procedure per se. Reported morbidity or mortality between open and endovascular techniques were similar. Intermediate and long-term mortality rates during follow-up of studies were high; over 10% of patients were dead at one year and almost half were dead at five years. Patients with diabetes and a foot ulcer should be optimised prior to revascularisation and given the systemic nature of their vascular disease they should also receive aggressive and appropriate medical management of risk factors to reduce their high long-term mortality.

Attempts have been made to categorize the distribution of PAD in patients with diabetes and correlate this with perfusion¹⁷. However, in most studies anatomical distribution pattern of the PAD, ABI, toe-pressure or TcPO₂ measurements, wound characteristics were reported poorly, although prospective studies have shown the impact of these factors on healing or amputation rate. Also many studies report major amputation or limb salvage as an outcome, but this is actually a treatment. The decision to perform such a procedure is likely to be influenced by factors such as infection, patient and doctor preferences as well as reimbursement. The standard reporting criteria for lower extremity ischemia are 15 years old and do not focus on factors that are specific to patients with diabetes⁹². Also minor amputations are part of management, particularly in case of infection, and improving blood

supply to the fore foot can help to limit tissue loss. But, we found no studies of sufficient quality on amputation level selection.

Many of the studies reported herein were from well recognized expert centres, biasing the results towards more favourable outcomes. Moreover, in some instances there was probably substantial overlap in the larger series of patients from certain centres. The data from the Swedvasc registry suggest that it is possible to attain good outcomes when revascularisation techniques are applied outside centres of expertise⁴⁴. However, such procedures should always be part of an integrated multifactorial approach that should include treatment of infection, debridement and off-loading to protect the wound from repetitive biomechanical stress.

Almost all studies were cases series with high risk of selection and publication bias. Case series comparing bypass surgery and endovascular treatment are difficult to compare because of indication bias. Several studies included in this review were retrospective analyses containing a small number of patients. Due to heterogeneity we could not pool the data. For ease of data presentation we provided the median and interquartile ranges of the results of the studies we selected, but this did not correct for number of patients, severity of disease and comorbidities. Due to these limitations we cannot give reliable estimates of expected outcome. Clearly, there is an urgent need for properly controlled studies with a well described population and outcomes which are relevant to patients with diabetes.

In conclusion, studies reported herein appear to demonstrate improved rates of limb salvage associated with revascularisation compared to the results of non-revascularized patients with diabetes, PAD and ulceration previously reported in the literature. High peri-operative morbidity and long-term mortality rates underline the importance of peri-operative optimisation and long-term medical management of patients' diabetes and comorbidities. Overall, there were insufficient data to recommend one method of revascularisation over another. There is need for standardised reporting of baseline demographic data, comorbidity, severity of disease and outcome reporting in this group of patients. A standardised wound classification system should be part of all future studies⁹³. These standards should take into account both the specific characteristics of the PAD and of the wound in these patients. Further efforts are also required to standardise and improve outcome reporting, which should

include wound healing, and it is important to move away from procedure specific outcomes to disease specific outcomes in this cohort of patients.

Conflict of interest: none declared.

Accepted Article

References

1. Hinchliffe RJ, Andros G, Apelqvist J, Bakker K, Fiedrichs S, Lammer J, Lepantalo M, Mills JL, Reekers J, Shearman CP, Valk G, Zierler RE, Schaper NC. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. *Diabetes Metab Res Rev.* 2012;28 Suppl 1:179-217
2. IWGDF Guidance on the Diagnosis, Prognosis and Management of Peripheral Arterial Disease in Patients with Foot Ulcers in Diabetes.
3. Prompers L, Schaper N, Apelqvist J, Jude E, Piaggese A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, van Baal J, van Merode F, Huijberts M Prediction of outcome in individuals with diabetic foot ulcers: focus on between individuals with and without peripheral vascular disease. The EURODIALE study. *Diabetologia* 2008; 51: 747-755
4. Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot? *Diabetes Metab Res Rev* 2000;16 Suppl 1:S75-83.
5. Welborn TA, Knuiman M, McCann V, Stanton K, Constable IJ. Clinical macrovascular disease in Caucasoid diabetic subjects: logistic regression analysis of risk variables. *Diabetologia* 1984; 27:568–573
6. Walters DP, Gatling W, Mullee MA, Hill RD. The prevalence, detection, and epidemiological correlates of peripheral vascular disease: a comparison of diabetic and non-diabetic subjects in an English community. *Diabet Med* 1992; 9: 710–715.,
7. Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter LM, Heine RJ. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn study. *Diabetologia* 1995; 38: 86–96.

8. American Diabetes Association. Peripheral arterial disease in people with diabetes. *Diabetes Care*. 2003 Dec;26(12):3333-41
9. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggese A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, van Baal J, van Merode F, Schaper N High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. *Diabetologia*. 2007;50:18-25
10. Jeffcoate WJ, Chipchase SY, Ince P, Game FL. Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures. *Diabetes Care*. 2006 29:1784-7.
11. Beckert S, Witte M, Wicke C, Königsrainer A, Coerper S: A new wound-based severity score for diabetic foot ulcers. *Diab Care* 2006; 29: 988-992,
12. Dolan NC, Liu K, Criqui MH, Greenland P, Guralnik JM, Chan C, Schneider JR, Mandapat AL, Martin G, McDermott MM. Peripheral artery disease, diabetes, and reduced lower extremity functioning. *Diabetes Care*. 2002;25:113-20
13. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. *Am Soc Nephrol*. 2007;18:629-36.
14. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggese A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Tennvall GR, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, Van Baal J, Van Merode F, Schaper N. Delivery of care to diabetic patients with foot ulcers in daily practice: results of the Eurodiale Study, a prospective cohort study. *Diabet Med*. 2008;25:700-7.
15. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. *Diabetes Care* 2003;26:491-4

16. Ruiter MS, van Golde JM, Schaper NC, Stehouwer CD, Huijberts MS Diabetes impairs arteriogenesis in the peripheral circulation: review of molecular mechanisms. *Clin Sci (Lond)*. 2010 Jun 8;119(6):225-38
17. Graziani L, Silvestro A, Bertone V, Manara E, Andreini R, Sigala A, Mingardi R, De Giglio R. Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity. *Eur J Vasc Endovasc Surg*. 2007 Apr;33(4):453-60
18. Faglia E, Mantero M, Caminiti M, Caravaggi C, De Giglio R, Pritelli C, Clerici G, Fratino P, De Cata P, Dalla Paola L, Mariani G, Poli M, Settembrini PG, Sciangula L, Morabito A, Graziani L. Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischaemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive diabetic subjects. *J Intern Med*. 2002;252:225-32
19. Jacqueminet S, Hartemann-Heurtier A, Izzillo R, Cluzel P, Golmard JL, Ha Van G, Koskas F, Grimaldi A: Percutaneous transluminal angioplasty in severe diabetic foot ischemia: outcomes and prognostic factors. *Diabetes Metab* 31:370-375, 2005
20. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; on behalf of the TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007;45(Suppl S):S5-S67
21. Bollinger A, Breddin K, Hess H, Heystraten FM, Kollath J, Konttila A, Pouliadis G, Marshall M, Mey T, Mietaschk A, Roth FJ, Schoop W. Semiquantitative assessment of lower limb atherosclerosis from routine angiographic images. *Atherosclerosis*. 1981 Feb-Mar;38(3-4):339-46
22. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009 Jul 21;339:b2535

23. Scottish Intercollegiate Guidelines Network 50: A guideline developer's handbook. <http://www.sign.ac.uk/guidelines/fulltext/50/section6.html>. Accessed 6th February 2011.
24. AhChong AK, Chiu KM, Wong MW, Hui HK, Yip AW. Diabetes and the outcome of infrainguinal bypass for critical limb ischaemia. *ANZ J Surg*. 2004 Mar;74(3):129-33
25. Alexandrescu V, Hubermont G, Philips Y, Guillaumie B, Ngongang Ch, Coessens V, Vandebossche P, Coulon M, Ledent G, Donnay JC. Combined primary subintimal and endoluminal angioplasty for ischaemic inferior-limb ulcers in diabetic patients: 5-year practice in a multidisciplinary 'diabetic-foot' service. *Eur J Vasc Endovasc Surg*. 2009 Apr;37(4):448-56
26. Bargellini I, Petrucci P, Scatena A, Cioni R, Cicorelli A, Vignali C, Rizzo L, Piaggese A, Bartolozzi C. Primary infrainguinal subintimal angioplasty in diabetic patients. *Cardiovasc Intervent Radiol*. 2008 Jul-Aug;31(4):713-22
27. Davidson JT 3rd, Callis JT. Arterial reconstruction of vessels in the foot and ankle. *Ann Surg*. 1993 Jun;217(6):699-708
28. Dosluoglu HH, Cherr GS, Lall P, Harris LM, Dryjski ML. Peroneal artery-only runoff following endovascular revascularizations is effective for limb salvage in patients with tissue loss. *J Vasc Surg*. 2008 Jul;48(1):137-43
29. Dorweiler B, Neufang A, Schmiedt W, Oelert H. Pedal arterial bypass for limb salvage in patients with diabetes mellitus. *Eur J Vasc Endovasc Surg*. 2002 Oct;24(4):309-13
30. Faglia E, Dalla Paola L, Clerici G, Clerissi J, Graziani L, Fusaro M, Gabrielli L, Losa S, Stella A, Gargiulo M, Mantero M, Caminiti M, Ninkovic S, Curci V, Morabito A. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. *Eur J Vasc Endovasc Surg*. 2005 Jun;29(6):620-7

31. Faglia E, Clerici G, Clerissi J, Gabrielli L, Losa S, Mantero M, Caminiti M, Curci V, Quarantiello A, Lupattelli T, Morabito A. Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study. *Diabetes Care*. 2009 May;32(5):822-7
32. Ferraresi R, Centola M, Ferlini M, Da Ros R, Caravaggi C, Assaloni R, Sganzaroli A, Pomidossi G, Bonanomi C, Danzi GB. Long-term outcomes after angioplasty of isolated, below-the-knee arteries in diabetic patients with critical limb ischaemia. *Eur J Vasc Endovasc Surg*. 2009 Mar;37(3):336-42
33. Gargiulo M, Maioli F, Ceccacci T, Morselli-Labate AM, Faggioli G, Freyrie A, Giovanetti F, Testi G, Muccini N, Stella A. What's next after optimal infrapopliteal angioplasty? Clinical and ultrasonographic results of a prospective single-center study. *J Endovasc Ther*. 2008 Jun;15(3):363-9.
34. Gibbons GW, Burgess AM, Guadagnoli E, Pomposelli FB Jr, Freeman DV, Campbell DR, Miller A, Marcaccio EJ Jr, Nordberg P, LoGerfo FW. Return to well-being and function after infrainguinal revascularization. *J Vasc Surg*. 1995 Jan;21(1):35-44
35. Hering J, Angelkort B, Keck N, Wilde J, Amann B. Long-term outcome of successful percutaneous transluminal angioplasty of the fibular artery in diabetic foot syndrome and single-vessel calf perfusion depends on doppler wave pattern at the forefoot. *Vasa*. 2010;39:67-75.
36. Hertzner NR, Bena JF, Karafa MT. A personal experience with the influence of diabetes and other factors on the outcome of infrainguinal bypass grafts for occlusive disease. *J Vasc Surg*. 2007 Aug;46(2):271-279
37. Hughes K, Domenig CM, Hamdan AD, Schermerhorn M, Aulivola B, Blattman S, Campbell DR, Scovell SD, LoGerfo FW, Pomposelli FB Jr. Bypass to plantar and tarsal arteries: an acceptable approach to limb salvage. *J Vasc Surg*. 2004 Dec;40(6):1149-57

38. Isaksson L, Lundgren F. Prognostic factors for failure of primary patency within a year of bypass to the foot in patients with diabetes and critical ischaemia. *Eur J Surg.* 2000 Feb;166(2):123-8
39. Jämsén T, Manninen H, Tulla H, Matsi P. The final outcome of primary infrainguinal percutaneous transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia. *J Vasc Interv Radiol.* 2002 May;13(5):455-63
40. Johnson BL, Glickman MH, Bandyk DF, Esses GE. Failure of foot salvage in patients with end-stage renal disease after surgical revascularization. *J Vasc Surg.* 1995 Sep;22(3):280-5
41. Kalra M, Gloviczki P, Bower TC, Panneton JM, Harmsen WS, Jenkins GD, Stanson AW, Toomey BJ, Canton LG. Limb salvage after successful pedal bypass grafting is associated with improved long-term survival. *J Vasc Surg.* 2001 Jan;33(1):6-16
42. Kandzari DE, Kiesz RS, Allie D, Walker C, Fail P, Ramaiah VG, Cardenas J, Vale J, Chopra A, Gammon RS. Procedural and clinical outcomes with catheter-based plaque excision in critical limb ischemia. *J Endovasc Ther.* 2006 Feb;13(1):12-22
43. Leers SA, Reifsnnyder T, Delmonte R, Caron M. Realistic expectations for pedal bypass grafts in patients with end-stage renal disease. *J Vasc Surg.* 1998 Dec;28(6):976-80
44. Malmstedt J, Leander K, Wahlberg E, Karlström L, Alfredsson L, Swedenborg J. Outcome after leg bypass surgery for critical limb ischemia is poor in patients with diabetes: a population-based cohort study. *Diabetes Care.* 2008 May;31(5):887-92
45. Mills JL, Gahtan V, Fujitani RM, Taylor SM, Bandyk DF. The utility and durability of vein bypass grafts originating from the popliteal artery for limb salvage. *Am J Surg.* 1994 Dec;168(6):646-50

46. Mohan CR, Hoballah JJ, Martinasevic M, Chalmers RT, Sharp WJ, Kresowik TF, Corson JD. Revascularization of the ischemic diabetic foot using popliteal artery inflow. *Int Angiol.* 1996 Jun;15(2):138-43.
47. Owens CD, Ho KJ, Kim S, Schanzer A, Lin J, Matros E, Belkin M, Conte MS. Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. *J Vasc Surg.* 2007 May;45(5):944-52
48. Panneton JM, Gloviczki P, Bower TC, Rhodes JM, Canton LG, Toomey BJ. Pedal bypass for limb salvage: impact of diabetes on long-term outcome. *Ann Vasc Surg.* 2000 Nov;14(6):640-7
49. Pomposelli FB Jr, Marcaccio EJ, Gibbons GW, Campbell DR, Freeman DV, Burgess AM, Miller A, LoGerfo FW. Dorsalis pedis arterial bypass: durable limb salvage for foot ischemia in patients with diabetes mellitus. *J Vasc Surg.* 1995 Mar;21(3):375-84
50. Pomposelli FB, Kansal N, Hamdan AD, Belfield A, Sheahan M, Campbell DR, Skillman JJ, Logerfo FW. A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1000 cases. *J Vasc Surg.* 2003 Feb;37(2):307-15
51. Pua U, Wong DE. Angioplasty in critical limb ischaemia: one-year limb salvage results. *Ann Acad Med Singapore.* 2008 Mar;37(3):224-9
52. Ramdev P, Rayan SS, Sheahan M, Hamdan AD, Logerfo FW, Akbari CM, Campbell DR, Pomposelli FB Jr. A decade experience with infrainguinal revascularization in a dialysis-dependent patient population. *J Vasc Surg.* 2002 Nov;36(5):969-74
53. Reed AB, Conte MS, Belkin M, Mannick JA, Whittemore AD, Donaldson MC. Usefulness of autogenous bypass grafts originating distal to the groin. *J Vasc Surg.* 2002 Jan;35(1):48-54
54. Rosenblum BI, Pomposelli FB Jr, Giurini JM, Gibbons GW, Freeman DV, Chrzan JS, Campbell DR, Habershaw GM, LoGerfo FW. Maximizing foot salvage by a

combined approach to foot ischemia and neuropathic ulceration in patients with diabetes. A 5-year experience. *Diabetes Care*. 1994 Sep;17(9):983-7

55. Saltzberg SS, Pomposelli FB Jr, Belfield AK, Sheahan MG, Campbell DR, Skillman JJ, LoGerfo FW, Hamdan AD. Outcome of lower-extremity revascularization in patients younger than 40 years in a predominantly diabetic population. *J Vasc Surg*. 2003 Nov;38(5):1056-9
56. Schneider JR, Walsh DB, McDaniel MD, Zwolak RM, Besso SR, Cronenwett JL. Pedal bypass versus tibial bypass with autogenous vein: a comparison of outcome and hemodynamic results. *J Vasc Surg*. 1993 Jun;17(6):1029-38
57. Schneider PA, Caps MT, Ogawa DY, Hayman ES. Intraoperative superficial femoral artery balloon angioplasty and popliteal to distal bypass graft: an option for combined open and endovascular treatment of diabetic gangrene. *J Vasc Surg*. 2001 May;33(5):955-62.
58. Sigala F, Georgopoulos S, Langer S, Baunach C, Papalambros E, Sigalas K, Bramis J, Bakoyiannis C, Bastounis E, Hepp W. Outcome of infrainguinal revascularization for critical limb ischemia in diabetics with end stage renal disease. *Vasa*. 2006 Feb;35(1):15-20.
59. Söderström M, Arvela E, Albäck A, Aho PS, Lepäntalo M. Healing of ischaemic tissue lesions after infrainguinal bypass surgery for critical leg ischaemia. *Eur J Vasc Endovasc Surg*. 2008 Jul;36(1):90-5.
60. Stonebridge PA, Tsoukas AI, Pomposelli FB Jr, Gibbons GW, Campbell DR, Freeman DV, Miller A, LoGerfo FW. Popliteal-to-distal bypass grafts for limb salvage in diabetics. *Eur J Vasc Surg*. 1991 Jun;5(3):265-9.
61. Tannenbaum GA, Pomposelli FB Jr, Marcaccio EJ, Gibbons GW, Campbell DR, Freeman DV, Miller A, LoGerfo FW. Safety of vein bypass grafting to the dorsal pedal artery in diabetic patients with foot infections. *J Vasc Surg*. 1992 Jun;15(6):982-

62. Taylor LM Jr, Porter JM. The clinical course of diabetics who require emergent foot surgery because of infection or ischemia. *J Vasc Surg.* 1987 Nov;6(5):454-9.
63. Toursarkissian B, Stefanidis D, Hagino RT, D'Ayala M, Schoolfield J, Shireman PK, Sykes MT. Early duplex-derived hemodynamic parameters after lower extremity bypass in diabetics: implications for mid-term outcomes. *Ann Vasc Surg.* 2002 Sep;16(5):601-7
64. Toursarkissian B, Jones WT, D'Ayala MD, Shireman PK, Harrison A, Schoolfield J, Sykes MT. Does the efficacy of dorsalis pedis artery bypasses vary among diabetic patients of different ethnic backgrounds? *Vasc Endovascular Surg.* 2002 May-Jun;36(3):207-12
65. Uccioli L, Gandini R, Giurato L, Fabiano S, Pampana E, Spallone V, Vainieri E, Simonetti G. Long-term outcomes of diabetic patients with critical limb ischaemia followed in a tertiary referral diabetic foot clinic. *Diabetes Care.* 2010 May;33(5):977-82
66. Verhelst R, Bruneau M, Nicolas AL, Frangi R, El Khoury G, Noirhomme P, Dion R. Popliteal-to-distal bypass grafts for limb salvage. *Ann Vasc Surg.* 1997 Sep;11(5):505-9.
67. Werneck CC, Lindsay TF. Tibial angioplasty for limb salvage in high-risk patients and cost analysis. *Ann Vasc Surg.* 2009 Sep-Oct;23(5):554-9
68. Woelfle KD, Lange G, Mayer H, Bruijnen H, Loeprecht H. Distal vein graft reconstruction for isolated tibioperoneal vessel occlusive disease in diabetics with critical foot ischaemia--does it work? *Eur J Vasc Surg.* 1993 Jul;7(4):409-13.
69. Wölfle KD, Bruijnen H, Reeps C, Reutemann S, Wack C, Campbell P, Loeprecht H, Häuser H, Bohndorf K. Tibioperoneal arterial lesions and critical foot ischaemia: successful management by the use of short vein grafts and percutaneous transluminal angioplasty. *Vasa.* 2000 Aug;29(3):207-14.

70. Woelfle KD, Bruijnen H, Loeprecht H. Infrapopliteal arterial occlusive disease in diabetics with critical foot ischaemia: The role of distal origin bypass grafts. *Vasa* 2001; Suppl.58:40-43
71. Zayed H, Halawa M, Maillardet L, Sidhu PS, Edmonds M, Rashid H. Improving limb salvage rate in diabetic patients with critical leg ischaemia using a multidisciplinary approach. *Int J Clin Pract.* 2009 Jun;63(6):855-8
72. Rigatelli G, Cardaioli P, Dell'avvocata F, Giordan M, Lisato G, Mollo F. Endovascular management of patients with coronary artery disease and diabetic foot syndrome: A long-term follow-up. *J Geriatr Cardiol.* 2011;8:78-81.
73. Park SW, Kim JS, Yun IJ, Hwang JJ, Lee SA, Chee HK, Chang SH, Shin DH, Jung HG, Chang IS. Clinical outcomes of endovascular treatments for critical limb ischemia with chronic total occlusive lesions limited to below-the-knee arteries. *Acta Radiol.* 2013;54:785-9.
74. Lejay A, Georg Y, Tartaglia E, Gaertner S, Geny B, Thaveau F, Chakfe N. Long-term outcomes of direct and indirect below-the-knee open revascularization based on the angiosome concept in diabetic patients with critical limb ischemia. *Ann Vasc Surg.* 2014;28:983-9.
75. Acín F, Varela C, López de Maturana I, de Haro J, Bleda S, Rodriguez-Padilla J. Results of infrapopliteal endovascular procedures performed in diabetic patients with critical limb ischemia and tissue loss from the perspective of an angiosome-oriented revascularization strategy. *Int J Vasc Med.* 2014;2014:270539
76. Söderström M1, Albäck A, Biancari F, Lappalainen K, Lepäntalo M, Venermo M. Angiosome-targeted infrapopliteal endovascular revascularization for treatment of diabetic foot ulcers. *J Vasc Surg* 2013;57:427-35.
77. Kabra A, Suresh KR, Vivekanand V, Vishnu M, Sumanth R, Nekkanti M. Outcomes of angiosome and non-angiosome targeted revascularization in critical lower limb ischemia. *J Vasc Surg.* 2013;57:44-9.

78. Zhan LX, Bharara M, White M, Bhatnagar S, Lepow B, Armstrong DG, Mills JL Sr. Comparison of initial hemodynamic response after endovascular therapy and open surgical bypass in patients with diabetes mellitus and critical limb ischemia. *J Vasc Surg.* 2012;56:380-6.
79. Alexandrescu V, Vincent G, Azdad K, Hubermont G, Ledent G, Ngongang C, Filimon AM. A reliable approach to diabetic neuroischemic foot wounds: below-the-knee angiosome-oriented angioplasty. *J Endovasc Ther.* 2011;18:376-87
80. Alexandrescu VA .Commentary: myths and proofs of angiosome applications in CLI: where do we stand? *J Endovasc Ther.* 2014:616-24
81. Gershater MA, Löndahl M, Nyberg P, Larsson J, Thörne J, Eneroth M, Apelqvist J. Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers: a cohort study. *Diabetologia.* 2009 Mar;52(3):398-407
82. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. *Diabetes Care.* 1998 May;21(5):855-9.
83. LoGerfo FW, Coffman JD. Current concepts. Vascular and microvascular disease of the foot in diabetes. Implications for foot care. *N Engl J Med.* 1984 Dec 20;311(25):1615-9
84. Lepäntalo M, Mätzke S. Outcome of unreconstructed chronic critical leg ischaemia. *Eur J Vasc Endovasc Surg.* 1996 Feb;11(2):153-7
85. Elgzyri T, Larsson J, Thörne J, Eriksson KF, Apelqvist J. Outcome of ischemic foot ulcer in diabetic patients who had no invasive vascular intervention. *Eur J Vasc Endovasc Surg.* 2013;46:110-7.

86. Albers M, Romiti M, Brochado-Neto FC, De Luccia N, Pereira CA. Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. *J Vasc Surg.* 2006 Mar;43(3):498-503.
87. Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. *J Vasc Surg.* 2008 May;47(5):975-981
88. Biancari F, Juvonen T. Angiosome-targeted lower limb revascularization for ischemic foot wounds: systematic review and meta-analysis. *Eur J Vasc Endovasc Surg.* 2014;47:517-22
89. Sumpio BE, Forsythe RO, Ziegler KR, van Baal JG, Lepantalo MJ, Hinchliffe RJ. Clinical implications of the angiosome model in peripheral vascular disease. *J Vasc Surg.* 2013;58:814-26.
90. Kagaya Y, Ohura N, Suga H, Eto H, Takushima A, Harii K. 'Real angiosome' assessment from peripheral tissue perfusion using tissue oxygen saturation foot-mapping in patients with critical limb ischemia. *Eur J Vasc Endovasc Surg.* 2014;47:433-41
91. Ndip A, Lavery LA, Boulton AJ. Diabetic foot disease in people with advanced nephropathy and those on renal dialysis. *Curr Diab Rep.* 2010 Aug;10(4):283-90
92. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. *J Vasc Surg.* 1997 Sep;26(3):517-38
93. Karthikesalingam A, Holt PJ, Moxey P, Jones KG, Thompson MM, Hinchliffe RJ. A systematic review of scoring systems for diabetic foot ulcers. *Diabet Med.* 2010 May;27(5):544-9

Appendix 1: Medline via OvidSP

Date of search: June 2014

File searched: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R); 1948 to Present

1. diabet*.ti,ab.
2. exp Diabetes Mellitus/
3. 1 or 2
4. (lower adj1 extremit*).ti,ab.
5. (lower adj5 limb*).ti,ab.
6. limb*.ti,ab.
7. leg*.ti,ab.
8. (foot or feet).ti,ab.
9. toe*.ti,ab.
10. Lower Extremity/
11. Leg/
12. Foot/
13. Toes/
14. Extremities/
15. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. 3 and 15
17. peripheral vascular disease*.ti,ab.
18. peripheral arterial disease*.ti,ab.
19. (pvd or povd).ti,ab.
20. (pad or paod or poad).ti,ab.
21. exp Peripheral Vascular Diseases/
22. (claudication or claudicant*).ti,ab.
23. exp Intermittent Claudication/
24. exp Arterial Occlusive Diseases/
25. exp Graft Occlusion, Vascular/
26. exp Saphenous Vein/
27. exp Femoral Artery/
28. exp Popliteal Artery/
29. 26 or 27 or 28
30. occlus*.ti,ab.
31. stenosis.ti,ab.
32. 30 or 31
33. 29 and 32
34. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 33
35. 15 and 34
36. 16 or 35
37. perfusion.ti,ab.
38. reperfusion.ti,ab.
39. exp Reperfusion/
40. (odema or edema or oedema).ti,ab.
41. exp Edema/
42. (swelling* or swollen).ti,ab.
43. inflamed.ti,ab.
44. inflammation.ti,ab.
45. (flow or flux).ti,ab.

46. exp Blood Flow Velocity/
47. capillar*.ti,ab.
48. exp Capillaries/
49. (ischem* or ischaem*).ti,ab.
50. exp Ischemia/
51. (by-pass or by-pass).ti,ab.
52. percutaneous.ti,ab.
53. angioplast*.ti,ab.
54. exp Angioplasty/
55. (ballon adj1 dilation).ti,ab.
56. (ballon adj1 dilatation).ti,ab.
57. exp Balloon Dilatation/
58. endotherapy.ti,ab.
59. endovascular.ti,ab.
60. evt.ti,ab.
61. (revascularization or revascularisation).ti,ab.
62. (endoscopic adj1 therapy).ti,ab.
63. exp Endoscopy/
64. atherectom*.ti,ab.
65. endarterectom*.ti,ab.
66. artherosclerosis.ti,ab.
67. exp Atherectomy/
68. stent*.ti,ab.
69. exp Stents/
70. patency.ti,ab.
71. exp Vascular Patency/
72. (limb adj1 salvage).ti,ab.
73. exp Limb Salvage/
74. subintimal.ti,ab.
75. surg*.ti,ab.
76. su.fs.
77. pta.ti,ab.
78. 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50
79. 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77
80. 36 and 78 and 79
81. (letter or comment or editorial or case reports).pt.
82. 80 not 81
83. limit 82 to humans

Appendix 2: Embase via OvidSP

Date of search: June 2014;

Database file searched: Embase 1980 to present

1. diabet*.ti,ab.
2. exp Diabetes Mellitus/
3. exp Diabetic Foot/
4. 1 or 3
5. (lower adj1 extremit*).ti,ab.
6. (lower adj1 limb*).ti,ab.
7. limb*.ti,ab.
8. leg.ti,ab.
9. (foot or feet).ti,ab.
10. exp Lower Extremity/
11. Leg/
12. Foot/
13. Toes/
14. toe*.ti,ab.
15. Extremities/
16. or/5-15
17. 4 and 16
18. peripheral vascular disease*.ti,ab.
19. peripheral arterial disease*.ti,ab.
20. (pvd or povd).ti,ab.
21. (pad or paod or poad).ti,ab.
22. exp peripheral vascular disease/
23. (claudication or claudicant).ti,ab.
24. exp intermittent claudication/
25. exp peripheral occlusive artery disease/
26. exp graft occlusion/
27. exp saphenous vein/
28. exp femoral artery/
29. exp popliteal artery/
30. 27 or 28 or 29
31. occlu*.ti,ab.
32. stenosis.ti,ab.
33. 31 or 32
34. 30 and 33
35. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 34
36. 16 and 35
37. 17 or 36
38. perfusion.ti,ab.
39. reperfusion.ti,ab.
40. exp reperfusion/
41. (odema or edema or oedema).ti,ab.
42. exp edema/
43. (swelling* or swollen).ti,ab.
44. inflamed.ti,ab.
45. inflammation.ti,ab.
46. (flow or flux).ti,ab.

47. exp blood flow velocity/
48. capillar*.ti,ab.
49. exp capillaries/
50. (ischemi* or ischaemi*).ti,ab.
51. exp ischemia/
52. or/38-51
53. (by-pass or bypass or by pass).ti,ab.
54. percutaneous.ti,ab.
55. angioplast*.ti,ab.
56. exp angioplasty/
57. (ballon adj1 dilation).ti,ab.
58. (ballon adj1 dilatation).ti,ab.
59. exp balloon dilatation/
60. endotherapy.ti,ab.
61. endovascular.ti,ab.
62. revasculari#ation.ti,ab.
63. (endoscopic adj1 therapy).ti,ab.
64. exp endoscopy/
65. artherosclerosis.ti,ab.
66. exp atherectomy/
67. stent*.ti,ab.
68. patency/
69. exp vascular patency/
70. exp stents/
71. patency.ti,ab.
72. (limb adj1 salvage).ti,ab.
73. exp limb salvage/
74. subintimal.ti,ab.
75. surg*.ti,ab.
76. su.fs.
77. pta.ti,ab.
78. or/53-77
79. 37 and 52 and 78
80. (Letter or Editorial).pt.
81. 79 not 80
82. limit 81 to human

Table 1: Evidence table

| Reference | Study design | Population (age, sex, number with diabetes) | PAD (distribution and severity) | Foot lesion | Comorbidities | Intervention and control management | Outcomes | Comment | Opinion |
|----------------------------|--|---|--|--|-------------------------------|--|---|--|---|
| AhChong 2004 ²⁴ | Case series 265 consecutive infrainguinal bypasses with outcomes described versus no diabetes | DM patients 176 No DM 89 Age median 74 (45-94) yrs versus 75 (29-94) no DM gender: 50% (88) male DM, 45 (51%) no DM (P=NS) | Distribution: NR Severity: ABI 0.43 Median toe pressure 26mm Hg (0-57) No scoring system used | Tissue loss 158 (90%) DM No DM 70 (79%) tissue loss (P=0.014) Ulcer score: NR Infection: NR | CAD 48% CVD 26% ESRD NR | Bypass graft to DM patients Fem-pop 44% Crural 40% Pedal 16% Autogenous vein 66% No DM Fem-pop 56% Crural 35% Pedal 9% (P=NS) Autogenous vein 63% | Median f/u 19months Mortality 30days 8% DM versus 1% No DM (P=0.04) Cardiovascular complications 9% v 4% (P=NS) Overall graft patency 1yr 63% Graft patency 4yrs 46% DM versus 34% no DM (P=0.19) Survival rate at 1,3,5 yrs 80%, 57%, 33% Ulcer healing: NR Limb salvage overall at 1 yr 83% for both groups and 5yrs 78% DM v 81% no DM (P=0.79) | Chinese population may differ from Western world Limited information about patient management | Early graft failure 6% 65 grafts failed overall during total study |

| | | | | | | | | |
|----------------------------------|--|--|---|--|---|---|--|---|
| Alexandr escu 2009 ²⁵ | Case series A retrospective case series of subintimal PTA and PTA in 161 patients with diabetes and ischaemic wound, PTA first approach | 161 DM patients age: > 70 years 41% gender: NR | Distribution: majority multilevel disease Severity: NR TASC classification reported | Wagner classification grade 2-4 in 104 limbs (59%) or as isolated calf ulcers in 42 cases (24%). In 30 (17%) limbs, complex below-the-knee trophic lesions were noted. Infection: NR | CVD 40 (22%) CAD 122 (69%) ESRD 33 (18%) dialysis | 161 procedures majority multilevel with 124 subintimal PTA (26 had single subintimal PTA) | Major amputation: NR Minor amputation: NR Complications: 8% peri-op Mean f/u 22 (SD 1) months Ulcer healing: 129 (73%) before end of study. Limb salvage: 12, 24, 36 and 48 month limb-salvage proportions: 89%, 83%, 80% and 80%. In an intention-to-treat analysis, the cumulative primary and secondary patency at 12, 24, 36 and 48 months were 62%, 45%, 41% and 38%, together with 80%, 69%, 66% and 66%, respectively. Major amputation: 24 (13%) during f/u | Level of intervention not described in all patients. Approximately 50% infrapopliteal or crural 70% neuropathy |
|----------------------------------|--|--|---|--|---|---|--|---|

| | | | | | | | | | |
|-------------------------------|---|---|----------------------------------|--|--------------------|---|---|---|---|
| Bargellini 2008 ²⁶ | Prospective case series of multilevel subintimal PTA in patients deemed not fit for surgical bypass | DM patients: 60 age: 69,4 (SD 9,4) gender: 68% (41) males | Distribution: NR Severity: NR | Fontaine: 100% Fontaine IV Infection: NR | CAD 42% CVD 25% | Subintimal PTA in patients not suitable for surgical bypass: Fem-pop level 56.7% (34) Infra-popliteal level 25% (15) Both levels combined 18,3% (11) | Mean follow-up 23 months (range, 0–48 months) Ulcer healing: 75% (45/60) Limb salvage: 93.3% (56/60) Major amputation: 3 within 30 days and 4 within 16 months Minor amputation: NR Complications: Peri-procedural mortality was 5% (3/60) Mortality at 1yr, 3yr 10%, 17% | Minor amputation: 67 (38%) 30-day mortality: 1% 1 and 2 year mortality: 7% and 19 % Major complication: 5% | How follow-up was performed, was not defined Long term mortality low for a "high risk" population medically unfit for bypass surgery |
|-------------------------------|---|---|----------------------------------|--|--------------------|---|---|---|---|

| | | | | | | | | | |
|---------------------------------|--|---|--|---|--|-------------------------------------|---|--|--|
| Davidson 1993 ²⁷ | Retrospective case series Bypass below knee case series | 54 DM patients (total population age 55-95; gender: 54% (38) men (total population) | Distribution: majority infrapopliteal severity: no information Infection: NR Ulcer score: NR | gangrene 56%, ulcer 28% (of total population) Infection: NR Ulcer score: NR | CAD 55%, CVD 27%, hemodialysis 7% (total population) | Vein graft below knee (57% to foot) | Limb salvage 90% at 12 months and 86% at 24 months Major complications: 9/70 Early graft failure n=3 (4.2%) Patency 93% 1yr and 85% 2yrs Mortality: NR | Follow-up duration was variable and after 1 year 29 limbs out of 58 limbs were available for evaluation and after 3 years 6 limbs out of 58. | Strengths and weaknesses: No data on patient, leg or ulcer characteristics in DM patients provided. Study with less than 80% with diabetes but limb salvage was reported separately for the diabetes patients in both groups |
| Dosluoglu 2008 ²⁸ | Case series A comparison of peroneal to other run-off vessels after PTA | 80 DM patients out of 111 age: NR gender: NR | Distribution: infrapopliteal Severity: NR TASC classification provided | All tissue loss Infection: NR | NR | Infrapopliteal PTA | F/U mean 19,2 (SD 13,4) months Ulcer healing: NR Limb salvage rate 75% in 24 months in diabetic patients with peroneal run-off and in run-off in other vessels 76% No other data on the diabetes sub-group divided | | |
| Dorweiler 2002 ²⁹ | Case series of pedal | DM patients 46 | Distribution: crural | All (100%) tissue loss | CAD 46% ESRD 13% | Pedal bypass with vein graft | F/U median 28 (1-70) months | No data on severity of | |

| | | | | | | | | | | | | |
|---------------------------|------------------------------------|---------------|--|----------------------------|-------------------------------------|--------------------|--|--|--|--|---|--|
| Faglia 2002 ¹⁹ | Case series Mixed series of PTA | bypass grafts | age: median 69yrs gender :78% (36) male | occlusions Severity: NR | Ulcer score: NR Infection: NR | CAD 55% ESRD 4% | PTA of stenoses greater than 50% diameter infra-inguinal | Ulcer healing: NR Limb salvage: 30 days 98%, 87% at 2 years Major amputation: 4 (3 within 30 days) Minor amputation: 70% Complications: peri-operative mortality 2% One patient failed graft within 30days Mortality at end of study 21/46 (47%) | Ulcer healing: NR Limb salvage: 30 days 98%, 87% at 2 years Major amputation: 4 (3 within 30 days) Minor amputation: 70% Complications: peri-operative mortality 2% One patient failed graft within 30days Mortality at end of study 21/46 (47%) | Ulcer healing: NR Limb salvage: 30 days 98%, 87% at 2 years Major amputation: 4 (3 within 30 days) Minor amputation: 70% Complications: peri-operative mortality 2% One patient failed graft within 30days Mortality at end of study 21/46 (47%) | PAD. No specific data on foot lesions Drop out and loss to f/u NR Well defined study | Probably significant amount of the data is also reported in Faglia 2009 221 had angio but 2 had no significant stenoses therefore 219 reported 28 subjects PTA not possible (9 |
|---------------------------|------------------------------------|---------------|--|----------------------------|-------------------------------------|--------------------|--|--|--|--|---|--|

| | | | | | | | | | | | |
|--------------------------------------|--|--|------------------------------|--|--|--------------------|---------------------------------------|---|--|---|--|
| Faglia ₂₀₀₅ ³⁰ | Retrospective case series Consecutive series of diabetic foot patients hospitalised. PTA as first choice revascularisation | DM patients 993 age: 65.5 (9.4) gender: 67% (663) male | ABI in 128 cases 0.53 (0.15) | 7% ilio-femoral 61% femoro-popliteal /crural 32% crural Severity: tcpO2 17,0 (11,9) | 88% tissue loss Texas classification I – 12% II – 16% III- 53% | CAD 62% ESRD 5% | PTA 68% procedures in crural arteries | Mortality 30days: 0% Mortality 5.3% at f/u Complications: n=1 (transient renal failure) | Mean f/u 26 (15.1) months Ulcer healing: 862/868 wounds healed Limb salvage: 98,3% during f/u Major amputations 2% during f/u Minor amputation: 48% Complications: 3.4% Mortality 30-day 0,1% Primary patency at 5yrs 88% (SD 9%) Mortality at 1 yr 6,7 % and 20,1% at 3 yrs | good wound description at presentation, n, level of disease : treated was well described some f/u data was obtained by treating physician telephone interview | surgery and 19 no candidate for any revasc) All ulcers healed with medical dressings of the 190 patients – nothing more specific Possibly some patients reported elsewhere Of the 993 treated with PTA only 10 did not manage to successfully get one vessel in line flow to the foot |
|--------------------------------------|--|--|------------------------------|--|--|--------------------|---------------------------------------|---|--|---|--|

| | | | | | | | | | |
|---------------------------|---|--|--|---|--|---|--|--|---|
| Faglia 2009 ³¹ | <p>Cohort with follow up 5,9 year (SD 1,28)</p> <p>Follow up study of 564 diabetic patients with „CLI“ referred for angiography. patients with obstruction more than 50% underwent PTA, when possible as first choice</p> | <p>PTA: 413 DM patients age:69,7 (SD 9,5) gender: 64,6% 267 males</p> <p>Bypass group: 114 DM patients age: 69.9 (SD 9.4) gender: 69,3% (79) males</p> <p>No revasc group: 27 DM patients age: 76.7 (SD 10.4) gender: 51,9% (14) males</p> | <p>Distribution:</p> <p>PTA: Iliac - femoral- popliteal axis in 28 patients (6.8%)</p> <p>Infra-popliteal in 137 patients (32,2%)</p> <p>Combination of both in 248 patients (60%)</p> <p>Bypass: NR</p> <p>No revasc: NR</p> <p>Severity: PTA: tcpO2 15,3 (11,9)</p> <p>Bypass: tcpO2 10,2 (10,3)</p> <p>No revasc: tcpO2: 7,0 (8,1)</p> <p>Scoring: NR</p> | <p>PTA: No lesion 62 (16%), rest Wagner 1-4 Infection: 65%</p> <p>Bypass: No lesion 16 (14%), rest Wagner 1-4 Infection 63%</p> <p>No revasc: No lesion 3 (11%), rest Wagner 1-4 Infection: 63%</p> | <p>PTA: Dialysis 24 (5,7%) CAD 225 (54,8%), CVD 53 (19%)</p> <p>Bypass: Dialysis 8 (7%); CAD 64 (59%); CVD 18 (15,8%)</p> <p>No revasc: Dialysis NR, CAD 24 (88,9%), CVD 9 (33,3%)</p> | <p>PTA, all stenoses > 50% were treated (see PAD distribution)</p> <p>Iliac-femoral- popliteal axis in 28 patients (6,8%)</p> <p>Infra-popliteal in 137 patients (32,2%)</p> <p>Combination of both in 248 patients (60%)</p> <p>Bypass, femoro- popliteal 58</p> <p>Fem- infrapopliteal 55</p> <p>Other 1</p> | <p>(extrapolated from Kaplan-Meier curve)</p> <p>Mean f/u 5,93 (SD 1,28) years of total cohort.</p> <p>No f/u data on the 3 subgroups</p> <p>PTA: Ulcer healing: NR</p> <p>Limb salvage: NR</p> <p>Major amputation: 1 month 2,3%; 8% at end of follow up</p> <p>Minor amputation: NR</p> <p>Complications: NR</p> <p>Bypass: Ulcer healing: NR</p> <p>Limb salvage: NR</p> <p>Major amputation: 1 month 5,4%; 21% at end of follow up</p> <p>Minor amputation: NR</p> <p>Complications: NR</p> <p>32% primary bypass failures</p> | <p>In addition authors analyzed their data as a case control study</p> | <p>The groups are the result of a stepwise treatment approach</p> <p>Statistical analyses do not seem systematically performed and analyses are missing. In particular, Kaplan-Meijer data are incomplete: number at risk at time points are missing.</p> <p>The study cannot be used as a cohort study comparing PTA vs bypass, it does however give information about the results of PTA and information of the revascularised vs non-revascularised patients</p> <p>Baseline characteristics of the groups</p> |
|---------------------------|---|--|--|---|--|---|--|--|---|

| | | | | | | | | | |
|------------------------------|--|--|---|---|---|-----------------------|---|--|---|
| Ferraresi 2009 ³² | Case series Long-term outcome of BK PTA in diabetes | 101 DM patients and 107 legs age: 66 (SD 9,4) gender: 84% (85) males | Distribution: Infrapopliteal Severity: tcpO2 18.1 (SD 11,2) Infection: NR | 34 ulcers, 74 gangrene Rutherford classification | CAD 28% CVD 4% ESRD 3% (dialysis) | PTA infrapopliteal | No revascularisation: Ulcer healing: NR Limb salvage: NR Major amputation: 59% at end of follow up Minor amputation: NR Complications: NR PTA vs. bypass p < 0,001 SIGN 2- | This case series is a sub analysis of a larger study | Strengths: Treated lesions clearly defined and standardised Patients with marked tissue loss Weaknesses: 1 and 3 year leg salvage and survival data are not provided, hindering interpretation. |
|------------------------------|--|--|---|---|---|-----------------------|---|--|---|

| | | | | | | | | | |
|-----------------------------|--|--|--|---|---------------------|--|---|--|---|
| Gargiulo 2008 ³³ | Prospective case series Outcome of successful tibial PTA in „CLI“ | 74 DM patients out of 87 total population age: 72 (SD 8,8) gender: 56% males | Distribution: NR Severity: NR | 92% Fontaine IV Ulcer classification: University of Texas Infection: NR | CAD 53% ESRD 28% | infrapopliteal PTA's (100%) combined with fem-pop angioplasty in 63% and in 3 (3,4%) patients combined with open revascularisation | Mean f/u 10,9 months (range 2 days-29 months) Ulcer healing: 74,9% at 1 year Limb salvage: 92,7% at 18 months Major amputation: 6,9% during f/u Minor amputation: NR Complications: No early perioperative complications | Only technically successful PTA included in the analysis | Strengths and weaknesses: Strengths: well performed prospective study with complete data set, provides relevant information on wound healing Weakness: the shortest follow-up data was 2 days, a Kaplan Meijer that includes duration of follow-up is missing, hampering interpretation |
| Gibbons 1995 ³⁴ | Retrospective case series Infra-inguinal bypass series Six months all patients were asked to fill in questionnaire on health related quality of life | 259 DM patients (total population 318) age: mean age 66years gender: 62.3% males | Distribution: Multilevel disease Severity: no information No score anatomical distribution | 237/318 (74.8%) ulcer or gangrene Infection: NR Ulcer score: NR | No information | infra-inguinal open revascularisation fempop 84 (26.4%) femtibial / peroneal 132 (41.5%) fempedal / plantar 100 (31.4%) | F/u 6 months Ulcer healing: NA Limb salvage: 97% at 6 months Minor amputation: NA 93% primary graft patency at 6months and secondary 97% | Walking devices used at start of study 63% and at end of 6months 74% 38% more active at f/u 32.5% about the same and 29.5% worse. | Selected group of patients: primarily HRQOL study |

| | | | | | | | | | |
|--|---|---|---|---|---|---|---|---|---|
| <p>(HRQOL)</p> <p>Hering 2010³⁵</p> | <p>Prospective case series of crural PTA in patients with diabetes and an(neuro-) ischemic foot ulcer</p> | <p>44 DM</p> <p>Age 72 (42-88yrs)</p> <p>Gender 75% (33) male</p> | <p>Distribution: NR</p> <p>Severity: NR</p> | <p>Wagner grade</p> <p>I – 0</p> <p>II – 6 (14%)</p> <p>III (30 (68%))</p> <p>IV – 8 (18%)</p> <p>Infection: NR</p> | <p>CAD 77%</p> <p>CVD 52%</p> <p>ESRD 16%</p> | <p>Peroneal PTA</p> | <p>Complications: morbidity peri-op 21%</p> <p>Mean F/u 23 (5-45) months</p> <p>Ulcer healing: 59%</p> <p>Limb salvage: 81%, 71% and 63% at 6, 12 and 18 months</p> <p>Mortality 30days: 9.1%</p> <p>Minor amputation: NR</p> <p>Complications: 1 renal failure</p> | <p>Less than half back to normal at 6months (47.4%)</p> | <p>A prognostic study of doppler waveform patterns predicting outcome of peroneal PTA</p> <p>Overall 50% had a restenosis or occlusion of peroneal artery</p> |
| <p>Hertzner 2007³⁶</p> | <p>Case series</p> <p>Mixed case series of bypass grafts</p> | <p>312 DM patients out of 650 (48%)</p> <p>age: NR</p> <p>gender: 62% males</p> | <p>Distribution: NR</p> <p>Severity: NR</p> | <p>71% ulceration or gangrene</p> <p>Ulcer score: NR</p> <p>Infection: NR</p> | <p>NR</p> | <p>infringuinal bypass grafts for occlusive disease</p> | <p>Median follow-up 4yrs</p> <p>Ulcer healing: NR</p> <p>Limb salvage: 73% (95% CI 67 – 78) at 5 years, 15 years 51% (38 – 64)</p> <p>Major amputation: 29 amputations in 201 diabetic patients</p> | | <p>Strengths and weaknesses: very long follow up time limited specific data on diabetics</p> |

| | | | | | | | | | | |
|-----------------------------|---|---|--|---|--------------------------|--|---|--|---|--|
| Hughes 2004 ³⁷ | Retrospective case series Series of pedal bypasses | DM patients 82 (84%), total 98 age: 68 (SD12) gender: 83% (81) male | Distribution: Crural Severity: NR No scoring | 93 (95%) tissue loss Infection: NR Ulcer classification: NR | CAD 40% ESRD 4% | Bypass to plantar and tarsal arteries with vein graft (one prosthetic) Popliteal inflow 72% | Minor amputation: NR Mortality 6.7% 30 days Mortality at end of study 83% at median 4yrs Complications: not reported separately for diabetes | Duration of f/u median 9 (1-112)months Ulcer healing: NR Mortality 30 days 1/98 total Complications: 124 peri-op complications Mortality at 1yr 9%, 5yrs 37% Limb salvage 75% 1yr, 69% 5yr Secondary patency 70% 1yr | Primary patency 41% and secondary patency of 50% at 5yrs Consecutive series of all revascularizations Excluded lost to f/u cases from analysis (n=26) | No differences in outcome between tarsal/plantar and dorsalis pedis bypass |
| Isaksson 2000 ³⁸ | Retrospective case | DM patients 43 (48 legs) | Distribution: NR | 7 (15%) rest pain | Prev MI 11 (26%), angina | Pedal bypass with vein | F/U up to 1yr | Short follow-up – | | |

| | | | | | | | | |
|---------------------------|---|---|---|--|---------------------|---|---|--|
| Jamsen 2002 ³⁹ | series Pedal bypass graft case series | age: 74 (40-84) gender: 37% (16) males | Severity: ABPI median 0.47 (0 – 2.14) Score: NR | All others (85%) tissue loss Ulcer score: NR Infection: NR | 6 (14%) | (proximal anastomosis femoral artery 20 (42%) and popliteal artery or below 28 (58%)) | Ulcer healing: Limb salvage: 1yr 85% Minor amputation: NR Complications at 30 days 2 died (4%), 1 patient MI Mortality rate at 1yr 14% Patency at 1yr 83% | early results only |
| | Retrospective case series Outcome of consecutive series of 100 infra-inguinal PTA considered suitable for PTA first approach | 100 patients (116 limbs) 76 (76%) DM patients age: 72 (38-90)yr total population gender: 40% (40) total population males | Distribution: NR Severity: ankle systolic pressure <50mm Hg Scoring system not used | Rest pain 23 (20%), ulcer 50 (43%), gangrene 43 (37%) Wound classification: NR Infection: NR | CAD 47%, CVD 28% | Angioplasty Femoropopliteal 54% Crural 17% Multilevel 29% | Median f/u 25months. Intention to treat analysis 1yr 67%, 3yr 63%, 5yr 56%, 8yr 45% limb salvage Ulcer healing: NR Limb salvage for endovascular treatments at 2, 3, and 5 years was 74%, 65% and 60% Major amputation: | 11 required bypass for PTA failure. Validity of 5 and 10 year questionable – very small numbers available after 3 years Pre selected to PTA first approach |

| | | | | | | | | | | |
|----------------------------|---|---|--|---|--|---|---|--|--|---|
| Johnson 1995 ⁴⁰ | Retrospective case series Retrospective review of popliteal distal bypass grafts in patients with ESRD | 43 DM patients In total population 53 age: 59 (total population) gender: 46% (27) males (total population) | Distribution: NR Severity: in general toe pressures <40, ABI <0.5 (or incompressible) Scoring NR | 69 limbs (53 with tissue loss) Ulcer score: NR | 43 ESRD (kidney transplant 10) CAD 38% CVD 15% | Total population 69 venous bypasses: Fem-pop 19 Crural 50 | Mean f/u 14 (range 3-96) months Ulcer healing: NR Limb salvage: 1yr 65% and 62% at 18 months Major amputation: 22 (foot amputations ^o) Minor amputation: NR | 32% during total f/u Minor amputation: 12% Major complications: 11% Mortality at 1,5 and 10 yrs 18%, 74%, 86% | 59% „foot amputations“ performed with patent graft | Amputation can be related not only to occlusion but also to other factors like infection. |
|----------------------------|---|---|--|---|--|---|---|--|--|---|

| | | | | | | | | | |
|--------------------------|---------------------------|--|--|---|---|---|---|--|--|
| Kalra 2001 ⁴¹ | Retrospective case series | Series of pedal bypass grafting using vein | DM patients 191 (75%), total population 256, 280 procedures age: median 70 (30-91) yrs total population gender: 68% (174) male total population Long grafts (prox above popliteal) 130 (46%) of total population Short grafts (prox anastomosis at or below popliteal) 150 (54%) of total population | Distribution: NR Severity: tcpO2 < 20mmHg in 88% and ABI =0.44 (38% incompressible) in 150 limbs Scoring system: NR | 90% tissue loss total population Infection: NR Wound classification: NR | CAD 132 (52%), CVD 54 (21%), ESRD 19 (7%) | All vein bypass grafts to pedal vessels | Median f/u 2.0 (range 0, 1-10, 1) years Cumulative limb salvage rates at 1, 3, and 5 years were 85% (95% CI, 80.3-89.5), 79% (95% CI, 73.9-85.1), and 78% (95% CI, 71.7-83.7), respectively Ulcer healing: NR Major amputation: 15% at 2.7years mean f/u Minor amputation: 12.4% Complications: 1.6% peri-op mortality Long-term mortality 1,3,5 yr = 13%, 24%, 40% Secondary patency at 1yr 78%, 3yr 72%, 5yr 71% | Survival rate was 65% if had patent graft at 5 yrs versus 26% if leg off 57% of patients had one or more secondary interventions for pedal graft |
|--------------------------|---------------------------|--|--|---|---|---|---|--|--|

| | | | | | | | | |
|-----------------------------|--|--|---|--|--|--|---|---|
| Kandzari 2006 ⁴² | Case series Endovascular revascularisation using catheter based plaque excision | 52 DM patients out of total pop of 69 age: 70 (SD 12) (total pop) gender: 49% males | Distribution: 154/160 lesions infrainguinal 43% crural Severity: ankle pressure < 50 mmHg | 93% Ruth 5 7% Ruth 6 (total pop) No ulcer classification | CAD 57% CVD 23% Infection: NR | endovascular plaque excision | F/u 6 months Ulcer healing: NR Limb salvage: NR Major amputation: 20% diabetes versus 18% no diabetes (p=0.86) at 6 months Minor amputation: NR Complications: major adverse events (26.7% diabetes versus 22.2% no diabetes, p=0.72). | Data reported comparing patients with and without diabetes however very little information given |
| Leers 1998 ⁴³ | Retrospective case series Pedal bypass grafts in ESRD | DM patients 31 (91%) 34 total age: 64 (39-85) yrs total population gender: male 59% total population | Distribution: infrapopliteal in 23 legs and infrainguinal in 13 legs of total population Severity (only in 16 patients): ABI 0.48 (0-0.95) mean, toe pressure 18 (0-78) | probably > 90% had tissue loss although this was not explicitly stated in the article Wound classification: NR Infection: NR | CAD: 28 (82%) ESRD: 100% (29 haemodialysis and 2 transplants) | Pedal venous bypass 88% total population | Average follow-up 13.5 (1-84) months Ulcer healing: NR Cumulative assisted primary patency at 1yr, 2yrs 62% and 62% Limb salvage: 56% at 1yr and 50% at 2yrs | Retrospective, some data were obtained from family or dialysis institutions Data difficult to interpret – self reported data |

| | | | | | | | | | |
|------------------------------|--|---|---|--|---|--|--|--|---|
| Malmstedt 2008 ⁴⁴ | part of country wide observational data base (Swedvasc) Outcome after bypass surgery in diabetics | 742 DM patients age: 74 (SD 9,8) gender: 58% male | Distribution: NR Severity: NR Infection: NR | 82% tissue loss Ulcer classification: NR | CAD 65% CVD 19% ESRD defined as creatinine 150 umol/L 20% | 261 femoral-popliteal bypasses 481 infra-popliteal bypasses | Major amputation: 16 (39%) at 13.5 months average f/u Minor amputation: 51 (26%) total population at 1yr Complications: Survival 64% at 1yr 1 periop death (2%) Mortality 36% at 1yr and 48% at 2yrs | Meat f/u 2,2 years Ulcer healing: NR Limb salvage: NR Major amputation: NR Minor amputation: NR Complications: NR | Composite primary endpoint was: amputation or death The rate of ipsilateral amputation or death was per 100 person years 30,2 (95% CI 26,6-34,2) Median time to life or limb loss was 2,3 years (CI 1,9-2,8) The use of the composite endpoint renders |
|------------------------------|--|---|---|--|---|--|--|--|---|

| | | | | | | | | |
|--------------------------|--|---|--|---|--------------------------------------|---|---|---|
| Mills 1994 ⁴⁵ | Retrospective case series of patients with popliteal distal vein bypass grafts | 46 DM patients (total population 53) age: 62.4 (total population) gender: 80% (37) men (total population) | Distribution: infra-popliteal Severity: NR Scoring distribution: NR | 52 tissue loss Infection: NR Ulcer score: NR | CAD 57%; ESRD 28% | Infra-popliteal vein bypass All crural bypass | Mean f/u 12.5 (range 1-66) months Ulcer healing: NR Limb salvage: 85% after 1 year (22 limbs out of 56 legs available at 1 year). Minor amputation: NR Complications: Peri-operative mortality: 2 out of 53 (3,6%) Within 30 days 2 graft occlusions with subsequent 2 major amputations Mortality 1yr 13%, and 2yr 29% | interpretation very difficult. Strength: well defined cohort Weaknesses: high rate withdrawal rate, probably combination of short duration and lost-to-follow-up (not reported separately) Paper is an example of the confusion between the total population, number of diabetics, number of extremities and number of procedures. |
| Mohan 1996 ⁴⁶ | Case series Pedal bypass graft case series | All DM patients 32 Mean age: 60 (range 42-84) yrs gender: 50% | Distribution: popliteal artery inflow AK pop 9 BK pop 26 Severity: NR | NR 18 (51%) ulcers 15 (43%) gangrene 2 (6%) patients rest pain | CAD 47% Chronic renal failure 28% | Popliteal to distal artery bypass PT 9 AT 8 DP 10 Peroneal 8 All vein grafts | Mean follow-up 24 (1-72) months Ulcer healing: NR 30day mortality | Small study population and no information regarding drop-out rate |

| | | | | | | | | |
|----------------------------|---|-------|-------------------------------------|-------------------------------------|--|--------------------------|--|---|
| Owen ⁴⁷ 2007 | Cohort study According to 4 different levels of kidney disease | males | Ulcer score: NR Infection: NR | Ulcer score: NR Infection: NR | 0% Limb salvage: 90% at 1yr, 82% at 3 years Major amputation: 5 within 20 months Minor amputation: NR Patency 1, 3yr 95%, 89% Complications: 4 failing grafts surgery revised. 3 bypass occlusions of which 2 resulted in major amputation 3 additional amp due to infection Mortality (longterm): NR | Infra-inguinal bypass | Mean f/u 69,2 (SD 28,5) months CKD 4 (eGFR 15-29): Ulcer healing: NR Limb salvage: at 5 year 77 (Sd14) Minor | A study that provides relevant data on CKD in severe forms as a prognostic factor. Infra-inguinal bypass, outflow data not provided |
|----------------------------|---|-------|-------------------------------------|-------------------------------------|--|--------------------------|--|---|

| | | | | | | | | | | |
|-----------------------------|---|---|--|-------------------------------------|--------------------------------|------------------------------|---|--|--|--|
| Panneton 2000 ⁴⁸ | Retrospective case series Pedal bypass graft series | DM patients 157 age: 66 (30-78) yrs gender: 71% (111) males | Distribution: NR Severity: NR Scoring system: NR | Ulcer score: NR Infection: NR | CAD 80 (51%), ESRD 41 (26%) | Pedal bypass graft with vein | Mean follow-up 2.7 yrs Ulcer healing: NR Limb salvage: 1yr 86%, 5yr 78% Minor amputation: NR Complications: 30-day mortality | A subgroup of a series comparing diabetics versus non-diabetics in which no differences were observed between the two groups | Comparison of diabetes and no diabetes | This study was reported as a case series Probably only sufficient data on CKD 5 patients Difficult to use patency data because mortality very high |
| | CKD 5 (eGFR < 15 and HD): 60 DM patients out of 72 (total cohort) age: 65 (SD 11) gender: 53% (38) males (total cohort) | | | Ulcer score: NR Infection: NR | | | amputation: NR Complications: 30 day mortality 3,1% CKD 5 (eGFR < 15 and HD): Ulcer healing: NR Limb salvage: at 5 year 50 (Sd 12) Minor amputation: NR Complications: 30 day mortality 4,2% CKD 5 mortality at 1yr 46%, 91% at 5yr SIGN 2- | | | |

| | | | | | | | | | | |
|-------------------------------|--|---|---|--|--|--------------------------------|--|--|--|---|
| Pomposelli 1995 ⁴⁹ | Case series Retrospective review of 367 consecutive patients undergoing 384 distal bypasses | 350 DM patients, total population 367 age: 58 mean gender: male 69% (253) | Distribution: NR Severity: NR Scoring: NR | 219 (72%) with ulcer; 47 (12%) of gangrene; 16% other indications Infection: 222 (55%) Ulcer classification: NR | Prior myocardial infarction 29%, CVD 12%, ESRD 5% (dialysis) of total population | Dorsalis pedis arterial bypass | 1.3%, MI 11 (7%), ARF 5 (3.2%), major amp 3 (1.8%) | Mean f/u 21 (range 2 -84) months Ulcer healing: NR Limb salvage: cumulative limb salvage rate 87% at 5 years, 1yr and 2yr estimated from K-M 90% and 85% | Comorbidity subdivided in various kinds of cardiovascular disease. | Large case series, long follow up period (5 years). Outcome is rather thoroughly described. Retrospective evaluation; not based on predifined problem; there is no drop out rate reported. Outcome limb salvage wasn't defined any further. |
| | | | | Secondary patency rates 82% at 5yrs Major amputation: 13 (3,5%) within 30 days. Total number of major amputations 30 (8,1%) within the 5 year follow up. Minor amputation: 75 (19%) Complications: 30-day mortality 1.8% myocardial | | | | | | |

| | | | | | | | | | | |
|---------------------------------|--|---|--|---|--|---|---|---|---------------------------------|--|
| Pompose III: 2003 ⁵⁰ | Retrospective case series Pedal bypass graft series | 865 total population 92% diabetes age: 67 years gender: 69% male | Distribution: inflow vessel 41% BK pop 29% CFA 12% AK pop 11% SFA Severity: NR No scoring | 78% ulcer Infection: NR Ulcer score: NR | CAD 47% ESRD 11% Of the total population | Sub group analysis of 1032 DP artery bypass All except 2 with vein | Mean f/u 23.6 (range 1-120) months Ulcer healing: NR Limb salvage: 78% at 5 yrs and 10yrs 58% Graft patency 85% 1yr Secondary patency at 5yrs 66% DM versus 56% no DM 51% and 76% mortality at 5 and 10yrs Minor amputation: NR Complications: 10 (1%) deaths within 30days 3% MI | infarction 5.4%. graft failures 7.5% at 30 days, Mortality 43% after 5yrs | 43 (4.2%) failed within 30 days | Sub-group analysis of a large 3731 bypasses to 1032 to DP arteries of which some were diabetic (865) |
| Pua 2008 ⁵¹ | Case series | 91% DM patients out | Distribution: NR | 37/46 patients with | 33% CAD 20% CVD | Mixed 25 5 crural | Mean f/u 13.3 (range 12-21) | 5 technical failures | Limited information | |

| | | | | | | | | |
|---------------------------|--|---|----------------------------------|--|---|---|--|---|
| Ramdey 2002 ⁵² | Consecutive patients receiving PTA for limb salvage | of 46 total age: NR gender: NR | Severity: NR No Score | foot lesions Ulcer score: NR Infection: NR | CAD 115 (65%) MI 64 (36%) CVD 27 (15%) ESRD: all patients | 16 fem-pop 3 aortoiliac | months Ulcer healing: at 13 months 66% patients with gangrene healed Limb salvage: 78% at 1 year. Mortality: NR Minor amputation: NR | regarding patient characteristics, comorbidity and selection procedures. Foot ulcers / gangrene are not specified any further. |
| | Prospective case series (registry) Infra-inguinal revascularization | DM patients; 92% out of a total population of 146 age: 63 years (SD 13) (total population) gender: 65% (Total population) | Distribution: NR Severity: NR | Tissue loss: 91% (total population) Ulcer score: NR Infection: 48% | Artery Inflow Iliac or femoral 123 (70%) Suprageniculate popliteal 20 (11%) Infrageniculate popliteal 34 (19%) Outflow Iliac/femoral 1 (0.6%) Suprageniculate popliteal 17 (10%) Infrageniculate popliteal 28 (16%) Tibial 50 (28%) Dorsalis pedis 80 (45%) Tarsal 1 (0.6%) | Follow-up: no data provided Complications: 30 day morbidity 23% 30 day mortality 5% Ulcer healing: NR Patency 1,3yr: 85, 68% Limb salvage: 1 yr 80% and 3yrs 80% Major amputation: 21 Minor amputation: NR | Follow-up not specified | |

| | | | | | | | | | |
|------------------------------|---|---|--|---|---|--|--|---|---|
| Reed 2002 ⁵³ | Retrospective case series Case series of bypass grafts originating distal to the groin | DM patients 140, total population 217, 249 procedures age: 65 (30-90) gender: 69% (140)male | Distribution: NR Severity: NR Scoring system: NR | Necrosis 127 (80%), rest pain 27 (17%) Infection: NR Wound classification: NR | CAD 95 (60%), ESRD 53 (33%) with 35 (23%) on dialysis | Infra-inguinal vein bypass graft Pedal (35%), Crural (60%) Femoropopliteal (4%), | Survival 60% 1 year, 3yrs 18% and only 5% alive at 5yrs Mean f/u 27months (range 1-180 months) 30 day mortality 0.6% Complications: major post-op morbidity 16 (10%) Ulcer healing: NR Limb salvage rate was 84% (SD +/-4) at 5years Minor amputation: NR 5yr patient survival was 44 (+/-5)% | Data extracted out of a cohort study comparing diabetics with non diabetics 21% secondary procedures | Major amputation was required in 9 patients with a patent graft |
| Rosenbaum 1994 ⁵⁴ | Retrospective case series Case series of infrapopliteal bypass | DM patients: 39 age: 62.3 (45-78) gender: 85% (33) males | Distribution: NR Severity: NR Score: NR | 100% tissue loss Ulcer score: Gibbons classification Infection: NR | NR | Peripheral bypass: 79% intra-popliteal Popliteal 19% Tibial/peroneal: 48% Dorsalis | Mean f/u 21,2 (2-64) months Ulcer healing: 40 limbs (of total 42 limbs) without foot surgery | Data of this study may be included in other reports of this group | No life-table analysis, no information about healing time, small series; follow-up procedures unclear |

| | | | | | | | | |
|------------------------------|---|---|---|---|--|--|---|---|
| Schneider 1993 ⁵⁶ | Case series of pedal bypass extracted from a cohort study that compares tibial with pedal | DM patients 45 of total population n=53 age: 67 (42-78) yrs total population gender: 73% (33) males of total population | Distribution: NR Severity: ABI 0.53 total population | 77% tissue loss Ulcer score: NR Infection: NR | CVD NR CAD NR ESRD NR | All pedal bypass graft with vein | heart failure: 1.32% Mortality at 1yr 12%, at 5yrs 27% | Major amputation defined as amputation proximal to metatarsals Low numbers of patients (6) at 5yrs |
| Schneider 2001 ⁵⁷ | Retrospective cohort Revascularization using either femoral distal bypass, combined SFA PTA and distal | SFA PTA plus short distal bypass DM patients 12 age: 70 (13) yrs gender: 83% male | Distribution: Combined: Below knee disease plus focal SFA disease (<3cm length) Severity ABPI 0.52 (0.19) Long distal | All gangrene Infection: NR Wound classification: NR | Combined CAD 33%, ESRD 58% Long distal CAD 38% ESRD 74% Short distal CAD 49% | Distal target vessels Combined Tibial – 25% Pedal 75% Long distal Tibial 57% Pedal 43% | Mean f/u 23 months Ulcer healing: NR Limb salvage at 2 years Combined 90 (9)% Long distal 78 | Small sample Heterogeneous populations – different distribution of PAD Confounding |

| | | | | | | | |
|---|---|--|---------------------------------|---|---|---|--|
| bypass grafting or short distal bypass graft. | Long distal bypass DM patients 46 age: 68 (11) yrs gender: 50% male Short distal bypass DM patients 52 age: 69 (11) yrs gender: 65% male | bypass: Extensive infra-inguinal disease involving fempop and infra-geniculate arteries Severity ABPI 0.42 (0.17) Short distal bypass: Severe infra-geniculate occlusive disease and patent fempop arteries Severity: ABPI 0.46 (SD 0.15) Scoring system: NR | ESRD 67% | Short distal Tibial 35% Pedal 65% | (9)% Short distal 98 (2)% Patency all procedures 78 (+/-5)% at 2yrs, 63 (8)% 5 yrs Minor amputation: NR Complications: NR Mortality: NR No differences between groups SIGN 2- | g by indication Drop out and loss to f/u not reported | |
| Sigala 2006 ⁵⁸ | Case series Mixed bypass graft plus 50 PTA All diabetics 97 with 121 procedures 66% male Mean age 68 (range 41 – 85) yrs | Distribution: Large variation Severity: NR | CAD 78% CVD 20% 100% ESRD | Infra-inguinal revascularisations Endovascular – 36% only 5% combination endo and open Bypass only 59% Crural artery 55% 10% crural artery only 28% femoropopliteal 18% ext iliac to femoropopliteal | Follow-up NR Ulcer healing: NR Limb salvage: 86% at 6 mo, 75% at 12, 56% 3 yrs Minor amputation: NR Complications 12/97 patients Mortality 30day 10%, 1yr 22%, 3yr 56% | Heterogeneous population of patients with wide variation of PAD distribution and revascularisation procedures All patients had ESRD Number of infections not stated in study but outcomes | |

| | | | | | | | | | |
|--------------------------------|--|---|---|--|---------------------|---|--|---|--|
| Soderstrom 2008 ⁵⁹ | Prospective case series Healing of ischaemic ulcers after infra-inguinal bypass surgery | 74 DM patients out of 148 total population age: NR gender: NR | Distribution: NR Severity: ABI < 0.5, systolic toe pressure < 30 mmHg. Fontaine 4 Classification: NR | Classification provided: All Fontaine IV ulcers Infection: NR | NR | Infra-inguinal bypass in all subjects, with 13 PTA inflow procedures (total population) | F/u 1 year Ulcer healing: 63% in 12 months in the diabetic patients Limb salvage: NR Major amputation: NR Minor amputation: NR Complications: NR Mortality: NR | Median time to achieve healing 213 days Diabetes was the only risk factor which delayed tissue healing (HR 0.5 95%CI 0.3-0.8 in multivariate analysis) | Arterial run-off for patients with diabetes not specified. No specific data on diabetic patients reported other than healing. |
| Stonebridge 1991 ⁶⁰ | Case series Retrospective review of 117 diabetic patients with a popliteal artery (or below) to distal bypass | All DM patients (117) age: 64 (27-92) gender: reported as male:female ratio 5:1 | Distribution: tibial Severity: NR Scoring: NR | non-healing 65 (52%), gangrene 20 (16%) infection: 40 (32%) foot abscess 2 (1.6%) osteomyelitis 6 (5%) Ulcer score: NR | CAD 32% ESRD 15% | Pop-distal bypass graft (129 procedures) | Mean f/u 13 (range 1-66) months Ulcer healing: NR Limb salvage: NR Major amputation: 8 during mean f/u 13 months: minor amputation: 34 Complications: operative mortality 0.8 %. | Non data about inclusion criteria according to PAD severity. | |

| | | | | | | | | | | |
|-------------------------------|--|--|---|---|----|-----------------------------|--|---|---|--|
| Tannenbaum 1992 ⁶¹ | Retrospective case series Case series of pedal bypass | DM patients 53 age: NR gender: 64% (34) male | Distribution: NR Severity: NR Score: NR | 73% ulcers, Infection: 45% cellulitis, 29% osteomyelitis, 20% gangrene, 2% abscess 11 minor amps performed pre bypass | NR | DP bypass with vein | Mean f/u 25 (SD 14) months 10 patients lost to f/u Limb salvage 1,2,3yr 98%, 98%, 95% Major amputation: NR Minor amputation: NR Patency 1,2,3yr 95%, 95%, 95% Complications: NR Mortality rate 1,2,3yr 5%, 16%, 16% | Study of acute sepsis in ischaemic diabetic feet Excellent limb survival and patient survival and healing No report on severity of PAD Wound infection 13% | 1yr and 3yr secondary patency rates 92% and 89% | |
| Taylor 1987 ⁶² | Retrospective case series Case series of 114 patients with infection, 43 of whom revascularised | DM patients 114 patients with a foot infection (138 limbs): 43 (48 limbs) with ischaemia and 71 | Distribution: NR Severity: NR But ischaemia was defined as absent pulses + ABI < 0.6 or TBI < 0.4 and abnormal wave forms | All infected ulcers Ulcer score: NR | NR | Peripheral bypass undefined | Mean f/u 3yrs (1-11yrs) Ulcer healing: NR Limb salvage: 2yrs 87%, 4yrs 73% | 17 lost to follow-up No data on lost to follow up on revascularised patients Much | | |

| | | | | | | | | | |
|---------------------|---|--|--|---|----------------------|--|--|----------------------------|-------------------------|
| Toursarkissian 2002 | Primarily a prognostic study of the use of duplex as a predictor of bypass graft failure in diabetics | DM patients 65 age: 61yrs gender: 40/64 (63%) males | Score: NR Distribution: NR Severity: toe brachial index 0.2 Score: NR | 61 (94%) tissue loss Infection: NR Ulcer score: NR | CAD 38%, ESRD 16% | 68 limbs Femoral to distal bypass 42 BK pop distal 16 Fem pop 10 All vein bypass | Major amputation: 9 (19%) at 3yr mean f/u Minor amputations due to infection Complications: NR Mortality rate at 1,3,5yr 19, 62, 84% Mean f/u 12 (SD 6months) Ulcer healing: NR Limb salvage: 80% at 1 yr Major amputation: 8/68 limbs at 12months (SD 6months) Minor amputation: NR Graft patency assisted primary 75% at 1 yr (estimate of Kaplan-Meier) Complications: nil Mortality: NR | important data missing 4/9 | 86% Hispanic population |
| Toursarkissian | Case series of pedal | 135 patients 144 | Distribution: NR | 96% tissue loss | CAD 62% ESRD 20% | Dorsalis pedis bypass grafts | Median f/u 8 (1-62) months | 82% hispanics | |

| | | | | | | | | | | |
|----------------------------|---|---|---|--|--------------------------------|--|--|--|--|--|
| 2002 ⁶⁴ | bypass | procedures all DM patients age: 62 (SD 11) yrs gender: 78% males | Severity: NR | Ulcer score: NR Infection: NR | CAD 42% CVD 23% ESRD 13% | 456/510 (89%) underwent attempted PTA 34%, 35%, 31% AK, BK, AK+BK PTA 1.8 (0.04) vessels treated per limb (total number of | Mean f/u 20 (13) months Ulcer healing: 61% at 9.4 (0.5) months and 7% at 23 months Major amputation 15% during f/u | Ulcer healing: NR Limb salvage: 83% at 30 months Major amputation: 19% at total f/u (mean 8 months) Minor amputation: 36% Patency : 70% 1yr, 68% 30 months Complications: 25 peri-op complications Mortality 30day 1.5% Mortality at end of study 10% | Study comparing outcome in various ethnic groups (hispanics versus no hispanics). Higher amp rate in hispanics | Good description of cohort. Outcomes better reported using K-M analysis. Of the 89.4% of |
| Uccioli 2010 ⁶⁵ | Retrospective case series of patients with diabetes and CLI and tissue loss treated using an endovascular first approach in | DM patients: 510 (100%) (total population 534 but 24 lost) age: 70 (0.8) gender: 64% male | Distribution: NR Severity: tcpO2 16mm Hg +/-0.8 Score: NR | 100% tissue loss Ulcer score: All class C/D and grade 2-3 of the Texas wound classification Infection: 79% | | | | | | |

| | | | | | | | | | |
|-----------------------------|------------------------|--|---|--|---|------------------------|--|---|---|
| Verhelst 1997 ⁶⁶ | a tertiary care clinic | Retrospective case series Case study of pedal and crural bypass graft | DM patients: 33 (92% of total population n=36) age: 62 (29-78) gender: 81% (29) males All data in this table as reported on total population | Distribution: NR Severity: tcpO2 18 mmHg +/- 7 Score: NR | 89% tissue loss Ulcer score: NR Infection: NR | CAD 44% Dialysis 4% | arterial stenoses 2.6 (0.06) per limb | Minor amputation: 54% Complications: NR Mortality 30d NR Mortality: 16% at 9 months | consecutive patients who were able to be treated using a PTA first approach, 11% had technical failure. 23% of PTA subintimal |
| | | | | | | | Popliteal-to-Distal venous Bypass Grafts (n=44): Posterior tibial: 13 Anterior tibial: 10 Peroneal: 6 Dorsalis pedis/plantar: 23 | Mean f/u 27 (1-65) months Ulcer healing: in 33/36 patients complete healing of skin lesions and that includes minor amputations. Limb salvage: 90, 82, 77% at 1, 3 and 5 years. Minor amputation: 92% Patency 1,3yr 87%, 74% | Confusion between patients/extremities. Small study. Mixture of vascular interventions. Started treating 33 patients – No standard error in curve and therefore high likelihood of significantl y small numbers during follow-up |
| | | | | | | | | Complications: MI 1 Heart failure 1 Post-operative bypass | |

| | | | | | | | | | |
|----------------------------|--|---|--|---|---|---|---|------------------------------------|---|
| Werneck 2009 ⁶⁷ | Case series Tibial PTA in patients with „CLI“ at „high risk“ retrospective case series | 40 DM patients (total population 49) age:70 gender: 71% males | Distribution: All had „severe“ tibial disease, „some also had femoropopliteal PAD“ Severity: NR TASC reported: | Classification: 20% Ruth 4 80% Ruth 5* Infection: NR | CAD 69% ESRD 73% of the total population | Tibial angioplasty in all and in 45% multilevel (femop segment) | occlusion and major amputation 3 Mortality 30days 0% Deaths: 4 during following follow-up | Angiographic success rate was 84%. | Number of pts with surgery vs. PTA not given. There were 10 amputations in patients with diabetes. However, it is unclear how many vases were in the PTA group. |
| | | | | | | | Mean f/u 7,7 (range 1-61,5) months Ulcer healing: NR Limb salvage: 76% after mean f/u 8months Cumulative limb salvage rate in tibial PTA only after 1yr: approx 70% estimated from Kaplan-Meier Minor amputation: NR Complications: major complications occurred in 6.1% 30day mortality 2% | | |

| | | | | | | | | |
|--------------------------|--|--|--|--|--|---|---|--|
| Woolf 1993 ⁶⁸ | Retrospective case series Case study of mixed bypass grafts | DM patients: 72 age: 70.5 gender: NR | Distribution: Isolated Tibioperoneal Vessel Occlusive Disease Severity: NR | All with minor tissue loss Ulcer score: NR Infection: NR | CAD 57% Symptomatic carotid disease: 21% ESRD (creat > 2 mg/dl): 25% | Distal Vein Graft Reconstruction: Proximal anastomosis: Below knee popliteal: 56 Anterior tibial: 18 Distal anastomosis: ATA 10 DPA 37 PTA 13 Peroneal: 12 Plantar 3 | Mortality after 1yr 10% Follow-up: no information provided how this was performed or data reported Ulcer healing: Limb salvage: at 30 days 93%, at 1 year 81%, 5yr 72% Patency: 30days 97%, 1yr 86%, 5yr 75% Minor amputation: NR Complications: mortality within 30 days 1,3% 23 patients died during follow-up (including post-op mortality) | ulcer healing not reported; total number of BK amputations not reported. No data on follow-up |
| Woolf 2000 ⁶⁹ | Retrospective case series of two different procedures Bypass crural versus PTA crural | Bypass DM patients 125 (130 grafts) age: 70 (50-87) yrs | Bypass Distribution: Crural Severity: NR PTA Distribution: | Bypass 127 tissue loss PTA 84 tissue loss | Bypass CAD 57% CVD 18% ESRD 25% PTA CAD 48% CVD 17% | Vein to DP in 63 or ant tibial artery in 20 and PT in 28 and in peroneal in 19 Angioplasty crural arteries | Average follow-up probably 24months Bypass Limb salvage 80% 1yr, 73% at 3yrs and 69% at | Poor information on loss to follow-up and drop out. Retrospecti |

| | | | | | | | |
|--|---|---|---|-----------------|---|--|--|
| | <p>gender: NR</p> <p>Distal PTA DM patients 74 (89 limbs), 84 total</p> <p>age: 68 (48- 89)</p> <p>gender: NR</p> | <p>Crural</p> <p>Severity: tcpO2 6.7 (0-29)</p> <p>Score: AHA</p> | <p>Ulcer score: NR</p> <p>Infection: NR</p> | <p>ESRD 42%</p> | <p>AHA classification (1994) 1 - 8 2 - 28 3 - 26 4 - 27</p> | <p>6yrs</p> <p>2.3% 30day mortality</p> <p>Patency 1,3,5yr = 76%, 70%, 60%</p> <p>30 major amputation at 24months Minor amputations: NR</p> <p>64 died during f/u</p> <p>PTA</p> <p>Limb salvage 1yr 82%, 77% at 3yrs and 77% at 5 years</p> <p>30day mortality 6%</p> <p>17 major amputations during 24months Minor amputations: NR</p> <p>26 deaths died during f/u</p> <p>Complications: Major haematoma 3 patients</p> | <p>ve case series of two different procedures and not a controlled study</p> |
|--|---|---|---|-----------------|---|--|--|

| | | | | | | | | |
|----------------------------|--|--|--|--|--|--|---|--|
| Woeifle 2001 ⁷⁰ | Retrospective case series Case studies infra-popliteal bypass graft | DM patients: 135 (143 procedures) age: 70 (50-89) gender: NR | Distribution: extensive infra-popliteal occlusions Severity: NR | Tissue loss in 140 limbs Ulcer score: NR Infection: NR | CAD 82 (61%), CVD 29 (20%), ESRD 43 (16%), | All venous bypass with proximal anastomosis: BK popliteal 113 ATA 29 PA 1 Distal anastomosis: ATA 21 DPA 71 PTA 29 Peroneal 22 PTA of SFA prior to surgery in 37 | Follow-up duration not reported Ulcer healing: NR Patency 1yr 83%, 5yr 60%, 7yr 51% Limb salvage rates 30 days 94%, 1 yr 80%, 5 yrs 74%, 7 yrs 64% Major amputation: 35 during follow-up Minor amputation: NR Complications: 30 day mortality 8% Mortality 1yr 27%, 5yr 70%, 7yr 82% | No data on mean duration of follow-up or on severity of PAD |
| Zayed 2009 ⁷¹ | Retrospective series Series of combined PTA and bypass surgery | DM patients: 312 age: 72 yrs (39-93) gender: males 60% (188) | Distribution: NR Severity: NR Classification: NR | 93% tissue loss Ulcer score: NR Infection: NR | CAD 107 (34%) Dialysis: 33 (10.5%) | 257 (82%) PTA, 55 (18%) surgical bypass open 20 had combination of both procedures | Follow-up not defined and no data reported Ulcer healing: NR Limb salvage: NR Major amputation: 13 | No data on follow-up PTA not specified, severity of PAD not described All amputation |

| | | | | | | | | | | |
|------------------------------|---|--|---|---|--|---|---|--|-------------------------|--|
| Rigatelli 2011 ⁷² | Retrospective case series Review of outcome of diabetic patients with PAD and treated with PTA | DM patients 220 age: 78.5 years (SD 15.8) gender: 51% male | Distribution: all infrapopliteal (with 52% triple vessel disease) 19% iliac, 42% femoral, 17% popliteal occlusive disease severity: ABI 0.29 (SD 0.6) TcPO2 16.5 mmHg (SD 10.6) | Fontaine IV 79.5% Fontaine III 20.5% Ulcer score: NR Infection: NR | CAD 39% Chronic renal failure (not specified) 21% | PTA, with immediate success (unspecified) in 95% Subintimal approach | Mean f/u 3.1 (SD 1.8) (range 1 to 5) years Ulcer healing: 92% Limb salvage: 98% Minor amputation: 15% Complications: 5% (including vessel rupture, AV fistula) Mortality: 12% during f/u Post PTA ABI: 0.82 (SD 0.2) Post PTA TcPO2: 35.3 mmHg (SD 14.5) | cases (4.1%), of these 7 had PTA, 6 had reconstructive vasc surgery Minor amputation: NR Complications: NR | s above or through knee | No description ulcer, outcome not defined, no survival analysis reported |
| Park | Retrospective | DM patients | Distribution: all | Rutherford 4: | CAD 27% | PTA, with | Mean f/u | Very few | Ulcer not | |

| | | | | | | | | | |
|--------------------------|--|--|--|---|--|---|--|--|---|
| 2013 ⁷³ | <p>case series of consecutive patients who underwent below infrapopliteal PTA.</p> <p>Patients with concomitant above knee occlusive disease were excluded</p> | <p>49, with 64 limbs in which PTA was performed</p> <p>age: mean 67.4 years</p> <p>gender: male 78%</p> | <p>infrapopliteal severity NR</p> | <p>27% Rutherford 5: 45% Rutherford 6: 28%</p> <p>Ulcer score: NR</p> <p>Infection: NR</p> | <p>Chronic renal failure (not specified): 22%</p> | <p>immediate success (unspecified) in 94%</p> <p>CT-angiogram every 6 months during follow-up</p> | <p>19.3 (SD 13.4) months</p> <p>Ulcer healing: NR</p> <p>Limb salvage: 91%</p> <p>Minor amputation: NR</p> <p>Major amputation 9% at unspecified time points</p> <p>Complications: none except haematoma (n=2), pseudoaneurysm (n=1), both disappeared during follow-up</p> <p>Primary patency rates at 6 and 12-months were 75 and 59%</p> <p>Mortality: none</p> | <p>clinical data, patency rate oriented report.</p> | <p>described, loss to follow-up unclear, no actuarial analysis reported on limb salvage</p> |
| Lejay ⁷⁴ 2013 | <p>Retrospective case series of consecutive below knee bypasses.</p> <p>Limbs were divided post-PTA, according</p> | <p>DM patients 54 in whom 58 bypass procedures were performed.</p> <p>DR group: 36 limbs</p> <p>IR group: 22 limbs</p> | <p>Distribution: all infra-popliteal</p> <p>Skin perfusion pressure: DR: 15 mmHg (SD 12) IR: 17 mmHg (SD 13)</p> | <p>Ulcer present: DR: 89% IR: 91%</p> <p>Ulcer score: DR: deep ulcers 58% IR: deep ulcers 18% (deep = two highest</p> | <p>DR CAD 53% CVD 11% ESRD 53%</p> <p>IR CAD 55% CVD 9% ESRD 55%</p> <p>No significant</p> | <p>See study design.</p> <p>Tibial artery as outflow artery: DR: 86% IR: 77%</p> | <p>Mean f/u all patients 20 months (SD 16), no data reported on DR/IR groups</p> <p>Median ulcer healing DR vs IR: 56 (SD 18) vs</p> | <p>Definition of ischemia unclear as technique of skin perfusion measurement not described</p> | <p>Conclusions are limited because of retrospective design, relative small number of patients and confounding by indication</p> |

| | | | | | | | | |
|-------------------------|---|---|--|--------------------|---|---|---|---|
| Acin 2014 ⁷⁵ | <p>the angiosome concept, in those with 1) flow to site of the ulcer by a feeding artery (direct revascularization, DR) 2) flow through collaterals (indirect revascularization IR)</p> | <p>age: DR: 68 years (SD 10) IR: 71 years (SD 10) gender: DR: male 69% IR: male 68%</p> | <p>grades of UT scoring system combined) p<0.04 gangrene: DR: 11% IR: 9% Infection DR: 69.5% IR: 13.6 p<0.02</p> | <p>differences</p> | <p>Supra-popliteal PTA 55% Infra-popliteal PTA 100% Multiple tibial revascularization attempts in 52% DR: 54%; IR with flow through collaterals: 26%; IR without collaterals: 20%</p> | <p>112 days (SD 45) (p<0.02) Limb salvage at 1 and 3 years DR vs IR: 91% vs 66% and 65% vs 24%, respectively (p<0.04) Minor amputations: DR 42%; IR 45% (ns) Complications: NR Mortality after 1,3 yrs DR 22% and 43 %; IR 35% and 75 % (ns) No difference in primary patency rates</p> | <p>All patients had critical limb ischemia according TASC, but how this diagnosis was made, is not reported. Ulcer healing at 12 months: in DR 66%, in IR through collaterals 68%, IR no collaterals 7% (p<0.01). Limb salvage</p> | <p>Multiple analyses were performed, without statistical correction, and it is unclear to which extent only hypotheses were tested that were a priori formulated.</p> |
|-------------------------|---|---|--|--------------------|---|---|---|---|

| | | | | | | | | | |
|-------------------------------|---|---|---|--|---|---|--|---|---|
| Söderström 2013 ⁷⁶ | Retrospective case series of consecutive technically successful primary PTA Limbs were | DM patients 226, with 250 consecutive limbs in which a revascularisation was performed and whom | Distribution: see Intervention and control management DR ABI 0.73 (SD 0.33) Toe pressure 41 | DR Heel ulcer 16% Extending to bone 60% Infection 38% IR Heel ulcer | DR CAD 57% CVD 24% GFR < 30mL/min/1.73m ² or dialysis 22% | PTA all infrapopliteal Additional PTA popliteal or suprapopliteal DR 28% IR 31% | F/u 1 year DR Ulcer healing at 12 months: 72% (SD 5) IR Ulcer healing at | Indication for PTA unclear; no data on mean follow-up in both groups and drop outs, | Many aspects of the cohort well described. Objective criteria for and data on observer variability in post-PTA limbs in DR/IR categories are lacking |
| | angiosome concept, in those with: 1) flow to ulcer by a feeding artery (direct revascularisation, DR) 2) flow through collaterals (indirect revascularisation IR) 3) IR without collaterals | | | DR Heel ulcer 16% Extending to bone 60% Infection 38% IR Heel ulcer | DR CAD 57% CVD 24% GFR < 30mL/min/1.73m ² or dialysis 22% | PTA all infrapopliteal Additional PTA popliteal or suprapopliteal DR 28% IR 31% | F/u 1 year DR Ulcer healing at 12 months: 72% (SD 5) IR Ulcer healing at | Indication for PTA unclear; no data on mean follow-up in both groups and drop outs, | Objective criteria for and data on observer variability in post-PTA limbs in DR/IR categories are lacking |
| | after 24 months in DR 89%, in IR through collaterals 85% and in IR no collaterals 59% (vs DR p < 0.05) Ulcer healing at 1 year 51% in single revascularisation attempts (SR) and 59% in multiple revascularisations (MR), ns. Limb salvage at 2 years SR 72% and MR 78%, ns Major adverse cardiovascular event at 30 days: SR 4.1%; MR 1.9%, ns Major amputation in total group at 30 days 2% Minor amputation in total group 28% Mortality: NR | | | DR Heel ulcer 16% Extending to bone 60% Infection 38% IR Heel ulcer | DR CAD 57% CVD 24% GFR < 30mL/min/1.73m ² or dialysis 22% | PTA all infrapopliteal Additional PTA popliteal or suprapopliteal DR 28% IR 31% | F/u 1 year DR Ulcer healing at 12 months: 72% (SD 5) IR Ulcer healing at | Indication for PTA unclear; no data on mean follow-up in both groups and drop outs, | Objective criteria for and data on observer variability in post-PTA limbs in DR/IR categories are lacking |

| | | | | | | | | | | |
|--------------------------------|--|---|--|---|--|---|---|--|---|---|
| <p>Kabra 2013⁷⁷</p> | <p>divided post-PTA, according to the angiosome concept, in those with 1) flow to site of the ulcer by a feeding artery (direct revascularization, DR) 2) flow through collaterals (indirect revascularization, IR)</p> <p>A propensity score was used for adjustment of differences in pre-treatment covariables in multivariate analysis and for 1:1 matching.</p> | <p>were considered unfit for infrainguinal bypass surgery or autologous vein grafts</p> <p>DR (n=121) age 68 (SD 12) gender 64% male</p> <p>IR (n=129) age 74 (SD 11) gender : 55% male</p> | <p>mmHg (SD 21)</p> <p>IR ABI 0.64 (SD 0.29)</p> <p>Toe pressure 36 mmHg (SD 19)</p> | <p>18% Extending to bone 50% Infection 40%</p> | <p>IR CAD 70% CVD 19% GFR < 30mL/min/1.73m² or dialysis 10%</p> <p>IR significantly older, more females, more frequently CAD but less frequently lower GFR</p> | <p>DR Open 62% Endovascular 33% Hybrid 5%</p> <p>IR Open 48% Endovascular</p> | <p>12 months: 46% (SD 6)</p> <p>With the propensity score 84 DR and IR pairs were matched, with respectively healing at 12 months 69% (SD 7) vs 47% (SD 7) (p< 0.03) with hazard ratio for healing in DR 1.97 (95% confidence interval, 1.34-2.90).</p> <p>Limb salvage in DR and IR 86% (SD 3) and 74% (SD 4), ns</p> <p>Mortality NR</p> | <p>but based on figure in article possibly without major differences</p> | <p>categorising post-PTA limbs in DR/IR categories are lacking</p> <p>Not reported if patients were lost to follow-up</p> | <p>Results difficult to interpret as the DR and IR groups do not seem to be balanced in clinical presentation and type of</p> |
| | <p>Case series of a patients with CLI selected for analysis because they had one crural artery crossing the</p> | <p>DR patients (n=39) diabetes: 77% age: NR gender: male 82%</p> | <p>Distribution: NR</p> <p>ABI (n=58): 0.5 (SD 0.3)</p> | <p>DR ulcer 59% gangrene 64% site of ischemia heel 5%</p> <p>IR</p> | <p>DR CAD 18%</p> <p>IR CAD 52% (p< 0.01 vs. DR)</p> | <p>DR Open 62% Endovascular 33% Hybrid 5%</p> <p>IR Open 48% Endovascular</p> | <p>Follow-up 6 months, with 6 patients lost to follow-up</p> <p>Overall 30-day mortality 6%</p> <p>DR</p> | <p>Highly selected series of patients, the DR and IR patient groups were not comparabl</p> | <p>Results difficult to interpret as the DR and IR groups do not seem to be balanced in clinical presentation and type of</p> | |

| | | | | | | | | | | | | | | | | | | | | | |
|-------------------------|--|---|--|---|---|--|---|--|--|---|---|--|---|--|--|---|---|--|---|---|---|
| Zhan 2012 ⁷⁸ | ankle after revascularisation, all other patients in the same time period were excluded. Patients were divided in those with 1) perfusion to the ischemic region by the source artery according to the angiosome concept (direct revascularisation, DR) 2) perfusion by other artery (indirect revascularisation IR) | IR patients (n=25) diabetes: 88% age: NR gender: male 84% | ulcer 88% (p < 0.2 vs DR) gangrene 20% (p < 0.001 vs DR) site of ischemia heel 40% (p < 0.001 vs DR) | Open CAD 36% Creatinin > 133 mmol/l 18% Endo CAD 44% Creatinin > 133 mmol/l 35% | Open Rutherford 5- 6 84% Endo Rutherford 5- 6 85% | Distribution: see intervention Open ABI baseline 0.5 (SD 0.2) Toe pressure 28.3 mmHg (SD 26.8) Endo ABI baseline | Open (n=31) DM patients 100% age 71 years (SD 10) gender male 61% Endo (n=78) DM patients 100% age 68 years | 48% Hybrid 4% No significant differences | ulcer 88% (p < 0.2 vs DR) gangrene 20% (p < 0.001 vs DR) site of ischemia heel 40% (p < 0.001 vs DR) | Open CAD 36% Creatinin > 133 mmol/l 18% Endo CAD 44% Creatinin > 133 mmol/l 35% | Open Rutherford 5- 6 84% Endo Rutherford 5- 6 85% | Distribution: see intervention Open ABI baseline 0.5 (SD 0.2) Toe pressure 28.3 mmHg (SD 26.8) Endo ABI baseline | Open (n=31) DM patients 100% age 71 years (SD 10) gender male 61% Endo (n=78) DM patients 100% age 68 years | 48% Hybrid 4% No significant differences | Ulcer healing: 96% Major amputation: 13% Mortality: 4% Lost to follow-up: 5% IR Ulcer healing: 83% Major amputation: 16% Mortality: 20% Lost to follow-up: 16% Significantly higher ulcer healing rate at 6 months in DR (p < 0.03) Minor amputation :NR | Mean F/u Open 13 (SD 12) months and Endo 15 (SD 12) months: Open, post-intervention ABI 0.90 (SD 0.18) Toe pressure 62.7 mmHg (SD | Open, level of intervention Aorta-iliac 10% Femoral-popliteal 35% Tibial 55% Endo, level of intervention Aorta-iliac 9% Femoral-popliteal 51% | Relative small numbers, selection bias likely as patients were not randomised, no data on PAD distribution; no data on | Results suggest that in selected patients the same short-term hemodynamic improvement in the foot can be improved with Endo as in Open. | intervention (although for the latter statistically no differences were observed). No correction was made for these differences in prognostic factors Objective criteria for and data on observer variability in categorising limbs in DR/IR categories are lacking | e: in IR more heel ulcers (p < 0.001) less ulcers (p < 0.02) but more gangrene (p < 0.001). Definitions of ulcer and gangrene not given, no data on severity of PAD in the DR and IR patients |
|-------------------------|--|---|--|---|---|--|---|--|--|---|---|--|---|--|--|---|---|--|---|---|---|

| | | | | | | | | | | |
|-----------------------------|--|---|---|--|--|--|---|---|--|--|
| <p>Alexandrescu 79 2011</p> | <p>Open Endo or revascularization (Open) procedures. 24 patients had multiple interventions and data were analysed per intervention (total n=109) ABI and toe pressure were measured directly before and within 6 weeks after the intervention</p> | <p>(SD 11) gender male 65% Patients with ABI > 1.3 excluded</p> | <p>0.51 (SD 0.27) Toe pressure 38.2 mmHg (SD 28.3) No significant differences</p> | <p>ATR+ Neuropathy 100% Cellulitis >2 cm 70% Deep ulcers 66% ATR- Neuropathy 100% Cellulitis >2 cm 66% Deep ulcers 64%</p> | <p>ATR+ CAD 88% CVD 23% ESRD 20% ATR- CAD 82% CVD 20% ESRD 15%</p> | <p>No significant differences</p> | <p>Tibial 40% 68% autologous venous material, 32% prosthetic material No significant differences in level of intervention</p> | <p>27.7) Endo, post-intervention ABI 0.86 (SD 0.26) Toe pressure 71.7 mmHg (SD 35.0) Major amputation rate in Open 11% and in Endo 11% No significant differences between Open Endo Minor amputation.: NR Mortality: NR</p> | <p>ABI and toe-pressure > 6 weeks post-intervention</p> | <p>No actuarial analysis performed</p> |
| <p>Alexandrescu 79 2011</p> | <p>Cohort of patients with diabetes treated with PTA according to angiosome-targeted revascularization (ATR+) protocol which was compared with a historical control group treated</p> | <p>ATR+ 134 DM Age NR > 70 yrs 55% Gender NR ATR- 98 DM age NR > 70 yrs 51% Gender NR</p> | <p>PAD majority had multilevel disease, infrapopliteal lesions: ATR+ infrapopliteal lesions: TASC B 9% TASC C 32% TASC D 59% tpo2 21.7 mmHg (range 19-39)</p> | <p>ATR+ Neuropathy 100% Cellulitis >2 cm 70% Deep ulcers 66% ATR- Neuropathy 100% Cellulitis >2 cm 66% Deep ulcers 64%</p> | <p>ATR+ CAD 88% CVD 23% ESRD 20% ATR- CAD 82% CVD 20% ESRD 15%</p> | <p>Below knee PTA in all subjects and above knee if indicated In 10% of the ATR+ patients the angiosome-oriented target artery could not be reopened and boundary vessels were treated</p> | <p>Overall 30-day mortality 2% ATR+ Mean f/u 54.7 (range 3-59) months Amputation at 1 yr 10%. During total follow-up HR for no amputation vs ARR- 2.32 (p<0.04) Limb salvage 97% Wound healing</p> | <p>Clinically well characterized cohorts, that seem well matched</p> | <p>Main weakness is the use of a historical control group. No actuarial analysis for wound healing and limb salvage Unusual definition of limb salvage (no major amputation + functional autonomy)</p> | |

| | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|---------------------------------|
| | before introduction of ATR protocol (ATR-) | | <p>ATR-infrapopliteal lesions: TASC B 7% TASC C 37% TASC D 54%</p> <p>tcpO2 25.1 mmHg (range 17–52)</p> | | | | <p>73% Mortality at 1 and 3 years: 7% and 29% Minor amputation: NR</p> <p>ATR- Mean f/u 35.8 (range 1–68) months Amputation at 1 yr 16% Limb salvage 85% (p<0.03 vs ART+)</p> <p>Wound healing 68% Mortality at 1 and 3 years: 10% and 35% Minor amputation: NR</p> | | Definition amputation not given |
|--|--|--|--|--|--|--|--|--|---------------------------------|




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram